Composition comprises sustained-release fine particles and manufacturing method thereof

ABSTRACT

The present invention relates to a composition comprising sustained-release fine particles, characterized in that it contains sustained-release fine particles that can be used in quick-disintegrating tablets in the buccal cavity, one or more fillers selected from the group consisting of sugars or sugar alcohols, and one or more binders for quick-disintegrating tablets in the buccal cavity selected from the group consisting of sugars of high moldability and water-soluble polymer substances, and in that the sustained-release fine particles are granulated with filler and binder for quick-disintegrating tablets in the buccal cavity, and a manufacturing method thereof.

CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims the benefit of U.S. provisional patentapplication No. 60/308,303 filed Jul. 27, 2001.

FIELD OF THE INVENTION

The present invention relates to a composition comprisingsustained-release fine particles for quick-disintegrating tablets in thebuccal cavity. In further detail, the present invention relates to acomposition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity, characterized in thatit comprises a granulation product of sustained-release fine particlesand one or two or more fillers selected from the group consisting ofsugars or sugar alcohols granulated with binder for quick-disintegratingtablets in the buccal cavity, and in that the ratio of ungranulatedsustained-release fine particles in the entire composition is 0 to 15%.

BACKGROUND OF THE INVENTION

The “sustained-release fine particles” of the present invention meansfine particles that contain a drug, have been submitted to various typesof sustained-release treatments, and have a mean particle diameter ofapproximately 0.1 μm to approximately 350 μm. The various types ofsustained-release treatments means treatment to give the quality of“sustained release” that is well known pharmaceutically. Treatment thathas given gradual drug releasability, treatment that has givengastrosolubility, treatment that has given enterosolubility, treatmentthat has given timed releasability, treatment that has givenreleasability that is a combination of these, and the like, can be givenas examples. Moreover, those that have been given enterosolubility arecalled “enteric sustained-release fine particles.”

Various types of disintegrating tablets in buccal cavity were previouslydeveloped so that they could be easily taken, even without water, bypersons with weak swallowing ability, including the elderly, children,and the like. Moreover, the demand for the use of an assortment of drugsin recent years has led to the need for providing the function ofsustained releasability to quick-disintegrating tablets in the buccalcavity.

First-generation quick-disintegrating tablets in the buccal cavity, forinstance, “Zydis™” marketed by R. P. Scherer, and the like, are known tobe pharmaceutical preparations manufactured by lyophilization. Thesefirst-generation quick-disintegrating tablets in the buccal cavity arebasically manufactured by lyophilization, or special drying, using asolution or suspension of the drug. Thus, the process of manufacture ina liquid state was essential, and there was no discussion of providingthe function of sustained releasability.

Various second-generation quick-disintegrating tablets in the buccalcavity are known, including those that use the function of disintegrants(Japanese Kokai Patent No. Hei 10-182436, International Early DisclosurePamphlet WO98/02185, and the like), those characterized in that asaccharide of high moldability is spray coated and/or granulated asbinder on a saccharide of low moldability and which can be humidifiedand dried when tablet strength is further necessary (International EarlyDisclosure Pamphlet WO 95/20380 (corresponding U.S. Pat. No. 5,576,014,Japanese Patent No. 312141), and the like, and these are manufactured bytableting. Consideration has been given to quick-disintegrating tabletsin the buccal cavity containing fine particles that have beensustained-release treated, for instance, coated by a polymer, in orderto solve the apparent contradictory problem of providing the function ofsustained releasability to these second-generation quick-disintegratingtablets in the buccal cavity. However, even though attempts have beenmade to simply mix fine particles that have been sustained-releasetreated with a filler for quick-disintegrating tablets in the buccalcavity and tablet this mixture, segregation occurs due to a differencein apparent specific gravity and a difference in fluidity between thefiller and the sustained-release fine particles during the tabletingprocess. The term “segregation” used here is the state where thesustained-release fine particles are not uniformly dispersed in thefiller and segregation occurs when they are not uniformly dispersed. Itis possible to confirm segregation by determining uniformity of contentof drugs that comprise tablets once tablets have been made. Forinstance, it can be said that if the coefficient of variation (CV %) ofthe amount of drug, which is shown below, is 0 to 3.5%, segregation willnot occur and if the coefficient of variation exceeds 3.5%, segregationwill occur. Various problems are produced with this segregation as thecause. For instance, there are the problems of (1) tableting pressurebeing propagated directly to the sustained-release fine particles due tocontact between the punch face and the sustained-release fine particlesduring tableting, or direct contact between sustained-release fineparticles themselves, resulting in destruction of the sustained-releasefine particles and acceleration of dissolution after they have been madeinto tablets, (2) the degree of destruction of the sustained-releasefine particles varying with the degree of segregation and therefore,controlled dissolution, which is the design goal of sustained-releasefine particle preparation, not being realized with good reproducibilityafter tablets are made, (3) there being fluctuations in the number ofsustained-release fine particles contained in one tablet and it beingimpossible to guarantee uniformity of drug content, and the like.

An invention relating to a method of manufacturing spherical fineparticles that are useful for manufacturing controlled-releasepharmaceutical preparations that are easy to take by a special tumblinggranulation method is disclosed in International Early DisclosurePamphlet WO00/24379. This pamphlet gives a manufacturing methodinvolving special tumbling granulation of these spherical fine particlesand shows that dissolution is controlled by coating spherical fineparticles and that these spherical fine particles can be used inquick-disintegrating tablets in the buccal cavity. However, our researchhas confirmed that the above-mentioned various problems occur and thepurpose cannot be accomplished if quick-disintegrating tables in thebuccal cavity simply contain spherical fine particles that have beensustained-release treated. Moreover, there is no disclosure orindication of specific means for dealing successfully with theseproblems in said specification.

Thus, although as yet unknown, there is a demand for introduction ofquick-disintegrating tablets in the buccal cavity comprisingsustained-release fine particles with which acceleration of the drugdissolution after being made into a tablet that is the result ofdestruction of sustained-release fine particles under tableting pressurewhen tablets are made is inhibited, and controlled dissolution, which isthe design goal of sustained-release fine particle preparation, isrealized with good reproducibility even after tablets are made, and withwhich uniformity of drug content is guaranteed.

BRIEF SUMMARY OF THE INVENTION

Under these circumstances, the inventors focused on studies ofquick-disintegrating tablets in the buccal cavity comprisingsustained-release fine particles and researched methods of preventingsegregation of sustained-release fine particles and filler used inquick-disintegrating tablets in the buccal cavity, which is the sourceof various problems. As a result of repeating a variety of experiments,they successfully completed the present invention upon discovering thatsegregation of sustained-release fine particles and filler can beprevented by preparing a granulation product comprisingsustained-release fine particles, several of which have aggregatedtogether during this granulation process, using a granulation processwhereby all or part of the surface of individual sustained-release fineparticles is covered with filler. The “granulation” here means to makegranules or powder the size and shape of which are virtually uniform. Asa result of further detailed studies, it was discovered that segregationof sustained-release fine particles and filler is prevented when theratio of ungranulated sustained-release fine particles in the entirecomposition that is eventually obtained is 0 to 15%. It had been thoughtthat usually segregation readily occurs as a result of an increase inthe difference in apparent specific gravity between the fine particlesand filler and deterioration of fluidity of the fine particles, and thelike, when several particles aggregate in this way. However, it was acomplete surprise that it is possible not only to guarantee uniformityof content when making tablets, but to also simultaneously neutralizepressure during tableting by avoiding direct contact between the punchface and sustained-release fine particles, or the sustained-release fineparticles themselves, and realize good reproducibility of controlleddissolution, which is the goal.

That is, the present invention relates to

1. a composition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity, characterized in thatit comprises the product of granulation of sustained-release fineparticles containing a drug and one or two or more fillers selected fromthe group consisting of sugars or sugar alcohols with a binder forquick-disintegrating tablets in the buccal cavity, and in that the ratioof ungranulated sustained-release fine particles in the entirecomposition is 0 to 15%,

2. the composition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity of above-mentioned 1,wherein the binder for quick-disintegrating tablets in the buccal cavityis one or two or more selected from the group consisting of saccharidesof high moldability, water-soluble polymer substances, and saccharideswith a low melting point,

3. the composition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity of above-mentioned 2,wherein the sugar or sugar alcohol is one or two or more selected fromthe group consisting of saccharides with low moldability, saccharideswith a high melting point, and saccharides with a low melting point,

4. the composition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity of above-mentioned 3,wherein the mixture ratio of sustained-release fine particles, filler,and binder for quick-disintegrating tablets in the buccal cavity is 1 to50%, 20 to 98%, and 1 to 30%, respectively,

5. the composition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity of above-mentioned 4,wherein the mean particle diameter of the sustained-release fineparticles is approximately 0.1 μm to approximately 350 μm,

6. the composition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity of above-mentioned 5,wherein the sustained-release fine particles consist of at least crystalcellulose particles, drug, and polymer substance,

7. the composition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity of above-mentioned 6,wherein the drug is tamsulosin hydrochloride,

8. the composition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity of above-mentioned 7,wherein the sustained-release fine particles are entericsustained-release fine particles,

9. the composition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity of above-mentioned 8,wherein the polymer substance is hydroxypropylmethyl cellulose, ethylcellulose, Eudragit L30D55, and Eudragit NE30D,

10. the composition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity of above-mentioned 9,wherein the binder for quick-disintegrating tablets in the buccal cavityis one or two or more selected from the group consisting of maltose,trehalose, sorbitol, and maltitol,

11. quick-disintegrating tablets in the buccal cavity consisting of thecomposition comprising sustained-release fine particles ofabove-mentioned 10,

12. the quick-disintegrating tablets in the buccal cavity ofabove-mentioned 11, characterized in that the coefficient of variation(CV %) of the amount of drug, which is an indicator of uniformity ofcontent, is 3.5% or less,

13. a method of manufacturing a composition comprising sustained-releasefine particles for quick-disintegrating tablets in the buccal cavity,characterized in that it comprises the product of granulation ofsustained-release fine particles containing a drug and one or two ormore fillers selected from the group consisting of sugars or sugaralcohols with a binder for quick-disintegrating tablets in the buccalcavity, and in that the ratio of ungranulated sustained-release fineparticles in the entire composition is 0 to 15%,

14. the method of manufacturing a composition comprisingsustained-release fine particles for quick-disintegrating tablets in thebuccal cavity of above-mentioned 13, wherein the binder forquick-disintegrating tablets in the buccal cavity is one or two or moreselected from the group consisting of saccharides of high moldability,water-soluble polymer substances, and saccharides with a low meltingpoint,

15. the method of manufacturing a composition comprisingsustained-release fine particles for quick-disintegrating tablets in thebuccal cavity of above-mentioned 14, wherein the sugar or sugar alcoholis one or two or more selected from the group consisting of saccharideswith low moldability, saccharides with a high melting point, andsaccharides with a low melting point,

16. the method of manufacturing a composition comprisingsustained-release fine particles for quick-disintegrating tablets in thebuccal cavity of above-mentioned 15, wherein the mixture ratio ofsustained-release fine particles, filler, and binder forquick-disintegrating tablets in the buccal cavity is 1 to 50%, 20 to98%, and 1 to 30%, respectively,

17. the method of manufacturing a composition comprisingsustained-release fine particles for quick-disintegrating tablets in thebuccal cavity of above-mentioned 16, wherein the mean particle diameterof the sustained-release fine particles is approximately 0.1 μm toapproximately 350 μm,

18. the method of manufacturing a composition comprisingsustained-release fine particles for quick-disintegrating tablets in thebuccal cavity of above-mentioned 17, wherein the sustained-release fineparticles consist of at least crystal cellulose particles, drug, andpolymer substance,

19. the method of manufacturing a composition comprisingsustained-release fine particles for quick-disintegrating tablets in thebuccal cavity of above-mentioned 18, wherein the drug is tamsulosinhydrochloride,

20. the method of manufacturing composition comprising sustained-releasefine particles for quick-disintegrating tablets in the buccal cavity ofabove-mentioned 19, wherein the sustained-release fine particles areenteric sustained-release fine particles,

21. the method of manufacturing a composition comprisingsustained-release fine particles for quick-disintegrating tablets in thebuccal cavity of above-mentioned 20, wherein the polymer substance ishydroxypropylmethyl cellulose, ethyl cellulose, Eudragit L30D55, andEudragit NE30D,

22. the method of manufacturing a composition comprisingsustained-release fine particles for quick-disintegrating tablets in thebuccal cavity of above-mentioned 21, wherein the binder forquick-disintegrating tablets in the buccal cavity is one or two or moreselected from the group consisting of maltose, trehalose, sorbitol, andmaltitol,

23. a method of manufacturing quick-disintegrating tablets in the buccalcavity consisting of the composition comprising sustained-release fineparticles of above-mentioned 22, and

24. the method of manufacturing quick-disintegrating tablets in thebuccal cavity of above-mentioned 23, characterized in that thecoefficient of variation (CV %) of the amount of drug, which is anindicator of uniformity of content, is 3.5% or less.

The “binder for quick-disintegrating tablets in the buccal cavity” ofthe present invention means of binders that are generally used, a binderthat is particularly useful in the preparation of quick-disintegratingtablets in the buccal cavity, and a variety is selected in relationshipwith the “filler” of the present invention. The details are describedbelow, including its embodiments.

The “ungranulated sustained-release fine particles” in the presentinvention means sustained-release fine particles that do not comprisegranulation product when sustained-release fine particles are granulatedtogether with filler using a binder for quick-disintegrating tablets inthe buccal cavity. Moreover, the ratio of “ungranulatedsustained-release fine particles” is calculated by the followingformulas using the values from determination of particle diameterdistribution of the sustained-release fine particles and quantitativeratio by particle diameter of the composition comprisingsustained-release fine particles by the following methods:Ratio of ungranulated sustained-release fine particles (%)=G ₁+Σ(G_(i+1)−(P _(i) −G _(i)))

Here, the estimation of Σ is obtained by calculation from i=1 andestimating the value up to the point before (G_(i+1)−(P_(i)−G_(i)))becomes negative.

P₁: sustained-release fine particle ratio on sieve with smallest openingsize within the particle diameter distribution of the sustained-releasefine particles (with the exception of that where it is 0%).

P₂: sustained-release fine particle ratio on sieve with second smallestopening size within particle diameter distribution of thesustained-release fine particles (with the exception of that where it is0%). The third, fourth and so on are referred to as P₃, P₄, and so on,and they are as a whole represented as P₁.

G₁: value of quantitative ratio by particle diameter distribution ofcomposition on sieve with the same opening size as P₁.

G₂:value of quantitative ratio by particle diameter distribution ofcomposition on sieve with same opening size as P₂; the third, fourth,and so on are referred to as G₃, G₄, and so on, and they are as a wholerepresented as G₁.

The “the ratio of ungranulated sustained-release fine particles in thetotal composition is brought to 15% or less” in the present invention inother words means that the ratio of sustained-release fine particlesthat are not granulated is low, that is, the majority ofsustained-release fine particles are contained in each granulationproduct. Moreover, it also means that segregation of sustained-releasefine particles and filler is inhibited.

“Granulation product” in the present invention means a granulationproduct consisting of sustained-release fine particles, filler, andbinder for quick-disintegrating tablets in the buccal cavity, andgranulation product that does not comprise sustained-release fineparticles is defined in particular as “granulation product that does notcomprise sustained-release fine particles.” That is, the specific formof the composition of the present invention is a mixture comprising“granulation product,” “ungranulated sustained-release fine particles,”and “granulation product that does not comprise sustained-release fineparticles.”

Moreover, the quick-disintegrating tablets in the buccal cavity in thepresent invention indicates tablets with which disintegration time inthe buccal cavity is 0 to 2 minutes, preferably 0 to 1 minute, and canbe those disclosed in International Early Disclosure PamphletWO98/02185, International Early Disclosure Pamphlet WO95/20380, KokaiPatent No. Hei 10-182436, U.S. patent application Ser. No. 10/142,081(corresponding International Patent Application No. PCT/JP02/04481), andthe like.

Moreover, the “acceleration of dissolution of sustained-release fineparticles is inhibited” and “controlled dissolution, which is the goal[of sustained-release fine particles], is realized” in the presentinvention means that there is not a difference between the dissolutionrate of the sustained-release fine particles and the dissolution rate ofthe quick-disintegrating tablets in the buccal cavity. Specifically,when dissolution tests of sustained-release fine particles andquick-disintegrating tablets in the buccal cavity comprising thesustained-release fine particles are performed and drug dissolution ofthe sustained-release fine particles is compared, the difference betweenthe dissolution rate of sustained-release fine particles and thedissolution rate of quick-disintegrating tablets in the buccal cavity is0 to 15% at each dissolution time where drug dissolution ofsustained-release fine particles is approximately 30%, approximately50%, and approximately 80%. If the sustained-release fine particles areenteric sustained-release fine particles, the above-mentioned evaluationcannot be performed under conditions of a pH of 1.2, the differencebetween the dissolution rate of the enteric sustained-release fineparticles and the dissolution rate of quick-disintegrating tablets inthe buccal cavity two hours after starting the dissolution experiment is0 to 10%.

Moreover, “good reproducibility” means that the same results areobtained, for instance, even with quick-disintegrating tablets in thebuccal cavity prepared on a different occasion, when the differencebetween dissolution of quick-disintegrating tablets in the buccal cavityand dissolution of sustained-release fine particles comprising thesetablets is compared as described above.

Moreover, the “coefficient of variation (CV %) of the amount of drug” inthe present invention is an indicator of uniformity of content. Tests ofuniformity of content described below are conducted and the CV % iscalculated by the following formula:CV %=(standard deviation of each content)/(mean content)×100

A “CV % of 0 to 3.5%” can be regarded as no segregation with fewfluctuations in drug content of the tablets that have been prepared, andit can be said that “uniformity of drug content is guaranteed.”Moreover, a “CV % exceeding 3.5%” can be regarded as segregation withlarge fluctuations in drug content, and it can be said that “uniformityof content is poor.” Incidentally, a “CV % of 0 to 3.5%” is theappropriate range of the coefficient of variation in the presentinvention, the number that appears to be necessary for quality assuranceand indicates that a composition with a constant drug content isobtained.

The composition comprising sustained-release fine particles of thepresent invention and manufacturing method thereof of the presentinvention will now be described in detail.

There are no particular restrictions to the drug used in the presentinvention as long as it is an active component requiring sustainedreleasability that is effective in terms of treatment or that iseffective in terms of prevention. Examples of this drug are hypnoticsedatives, sleep-inducing agents, anti-anxiety drugs, anti-epilepsydrugs, antidepressants, anti-Parkinson's drugs, psychoneurotic drugs,central nervous system drugs, local anesthetics, skeletal musclerelaxants, autonomic nerve drugs, antipyretic analgesicanti-inflammatory agents, antispasmodics, anti-vertigo drugs,cardiotonics, drugs for arrhythmia, diuretics, hypotensives,vasoconstrictors, vasodilators, drugs for the circulatory system, drugsfor hyperlipidemia, drugs to promote respiration, antitussives,expectorants, antitussive expectorants, bronchodilators, antidiarrhealagents, drugs for controlling intestinal function, drugs for pepticulcer, stomachics, antacids, laxatives, cholagogues, gastrointestinaldrugs, adrenocortical hormones, hormones, urogenital drugs, vitamins,hemostatics, drugs for liver disease, drugs used for gout, drugs usedfor diabetes, antihistamines, antibiotics, antibacterials, drugs usedagainst malignant tumors, chemotherapeutic drugs, multisymptom coldmedications, nutrition-enhancing health drugs, osteoporosis drugs, andthe like. Examples of these drugs are anti-inflammatory, antipyreticantispasmodics or analgesics, such as indomethacin, diclofenac,diclofenac sodium, codeine, ibuprofen, phenylbutazone, oxyfenbutazone,mepirizole, aspirin, idensamide, acetaminophen, aminopyrine, phenacetin,butyl scopolamine bromide, morphine, etomidoline, pentazocine,fenoprofen calcium, naproxen, celecoxib, vardecoxib, tramadole, and thelike, anti-rheumatic drugs, such as etodolac, and the like,anti-tuberculosis drugs, such as isoniazide, ethambutol chloride, andthe like, drugs for the circulatory system, such as isosorbid nitrate,nitroglycerin, nifedipine, bardnidipine hydrochloride, nicardipinehydrochloride, dipyridamile, amrinone, indenolol hydrochloride,hydralazine hydrochloride, methyl dopa, furosemide, spironolactone,guanetidine nitrate, resperine, amosulalol hydrochloride, lisinoopril,methoprolol, pilocarbpine, tasosartan, and the like, psychoneuroticdrugs, such as chlorpromazine hydrochloride, amitriptylinehydrochloride, nemonapride, haloperidole, moperone hydrochloride,perphenazine, diazepam, lorazepam, chlordiazepoxide, adinazolam,alprazolam, methylphenidate, milnasivran, peroxetin, risperidone, sodiumvalproate, and the like, antiemetics, such as methoclopramide,ramosetron hydrochloride, granisetron hydrochloride, ondansetronhydrochloride, azasetron hydrochloride, and the like, antihistamines,such as chlorpheniramine maleate, diphenhydramine hydrochloride, and thelike, vitamins, such as thiamine nitrate, tocopherol hydrochloride,sicotiamine, pyridoxal phosphate, cobamamide, ascorbic acid,nicotinamide, and the like, antigout drugs, such as allopurinol,colchicine, probenamide, and the like, anti-Parkinson's drugs, such aslevo dopa, selegiline, and the like, hypnotic sedatives, such asamobarbital, bromwarelyl urea, midazolam, chloral hydrate, and the like,anti-malignant tumor drugs, such as fluorouracil, carmofur, aclarubicinhydrochloride, cyclophosphamide, thiotepa, and the like, anti-allergydrugs, such as pseudoephedrine, terfenadine, and the like,antidepressants, such as phenyl propanolamine, ephedrins, and the like,drugs used to treat diabetes, such acethexamide, insulin, torbutamide,desmopressine, glibizide, and the like, diuretics, such ashydrochlorthiazide, polythiazide, triaterene, and the like,bronchodilators, such as aminophyllin, formoterol fumarate,theophylline, and the like, antitussives, such as codeine phosphate,noscapine, dimemorphan phosphate, dextromethorphan, and the like,antiarrythmia drugs, such as quinidine nitrate, digitoxin, propafenonehydrochloride, procainamide, and the like, surface anesthetics, such asaminoethyl benzoate, lidocaine, dibucaine hydrochloride, and the like,antiepilepsy drugs, such as phenytoin, etosuccimide, primidone, and thelike, synthetic corticosteroids, such as hydrocortisone, prednisone,triamcinolone, betamethasone, and the like, drugs for the digestivetract, such as famotidine, ranitidine hydrochloride, dimethisone,sucralfate, sulpiride, tepronone, praunotol, 5-aminosalicylic acid,sulfasalazine, omeprazole, lannoprazole, and the like, drugs for thecentral nervous system, such as indeloxazine, idebenone, thiapridehydrochloride, bifermerane hydrochloride, calcium homopanthothenate, andthe like, agents for treatment of hyperlipidemia, such as pravastatinsodium, sinvastatin, lovastatin, prevastatin, atorvastatin, and thelike, antibiotics, such as ampicillin phthalizyl hydrochloride,cefotetan, josamycin, and the like, BPH therapeutic agents, such astamsulosin hydrochloride, doxazocin mesilate, terazosine hydrochloride,and the like, anti-asthma drugs, such as pranrucast, zafirlukast,albuterol, ambrozole, budesonide, leverbuterol, and the like,prostaglandin I derivative agents for improving peripheral circulation,such as beraprost sodium, and the like, antithrombotics, hypotensives,agents for treatment of heart failure, agents for treatment of variouscomplications of diabetes, agents for treatment of peptic ulcer, agentsfor treatment of skin ulcers, agents for treatment of hyperlipidemia,anti-asthma agents, and the like. The drug can be used in free form oras any salt that is pharmaceutically acceptable.

Moreover, the present invention can comprise drugs that do not requiresustained-releasability. Furthermore, one or a combination of two ormore drugs can be used. There are no special restrictions to the amountof this drug as long as it is the amount that is usually effective fortreatment, but it is preferably 50 w/w % or less, preferably 20 w/w % orless, in terms of tablet weight. For instance, when it exceeds 50 w/w %in terms of tablet weight, the ratio of fine particles to filler is highand granulation by the filler will be insufficient.

These drugs are sustained-release treated and contained in thesustained-release fine particles as fine particles with which release ofthe drug is controlled by the conventional methods described below.There are no special restrictions to the particle diameter of thesustained-release fine particles as long as it is within a range withwhich there is not a gritty feeling in the buccal cavity. Usuallyapproximately 0.1 μm to approximately 350 μm is preferred, approximately5 μm to approximately 250 μm is more preferred, and approximately 50 μmto approximately 250 μm is further preferred as the mean particlediameter. If it is smaller than 0.1 μm, it will be difficult to providesustained releasability with the current pharmaceutical technology,while if it is larger than 350 μm, it will have a very uncomfortablefeeling, such as a gritty feeling, in the buccal cavity.

Moreover, the sustained-release fine particles of the present inventioncan be prepared by conventional methods. For instance, sustained-releasefine particles can be made by the agitation granulation method ortumbling fluidized granulation method after adding polymer solution todrug and microcrystalline cellulose, as disclosed in Japanese Patent No.Hei 7-72129 (corresponding U.S. Pat. No. 4,772,475) and InternationalEarly Disclosure Pamphlet WO00/24379, or sustained-release fineparticles can be made by layering and coating drug over commercialmicrocrystalline cellulose particles (avicel particles, Asahi Kasei,brand name Celphere 102, and the like) as the core by conventionalcoating methods, such as fluidized bed coating, tumbling fluidizedcoating, and the like, and then further coating with polymer substanceto form a controlled-release film (Avicel Jiho, No. 40, P. 16-33, AsahiKasei Corp.). Moreover, it is also possible to use a conventionalcrystalline filler of approximately 1 μm˜approximately 150 μm,specifically crystalline lactose, granular sugar, sodium chloride, cornstarch, silicon dioxide (silica gel), and the like, taking intoconsideration the size of the sustained-release fine particles(approximately 0.1 to approximately 350 μm). Pre-coating withwater-soluble polymer substance, water-insoluble polymer substance, andthe like, can also be used in order to round the edges of the filler,which becomes the core, in this case. In addition, it is also possibleto make sustained-release fine particles by spray drying a solution orsuspension of drug and polymer substance using appropriate equipment,such as a spray dryer, and the like. Examples of solvents used toprepare these sustained-release fine particles are water, organicsolvent, and the like. Examples of organic solvents are alcohols,specifically, methanol, ethanol, propanol, isopropanol, and the like,halogenated alkanes, specifically dichloromethane, chloroform,chloroethane, trichloroethane, carbon tetrachloride, and the like,ketones, specifically acetone, methyl ethyl ketone, and the like,nitrites, specifically acetonitrile, and the like, and hydrocarbons,specifically n-hexane, cyclohexane, and the like. One or a mixture at anappropriate ratio of two or more of these organic solvents can be used,and they can also be used as a mixture with water at an appropriatepercentage.

The polymer substance used to prepare the sustained-release fineparticles can be selected as needed in accordance with the purpose ofuse. Examples are water-insoluble polymers, gastrosoluble polymers,enterosoluble polymers, wax-like substances, and the like. Examples ofwater-insoluble polymers are water-insoluble cellulose ether, such asethyl cellulose, Aquacoat (brand name, Asahi Kasei), and the like,water-insoluble acrylic acid copolymers, such as ethyl acrylate-methylmethacrylate-trimethyl ammonium chloride ethyl methacrylate copolymer(for instance, brand name of Eudragit RS, Röhm), methylmethacrylate-ethyl acrylate copolymer dispersion (for instance, brandname: Eudragit NE30D, Röhm), and the like, and the like. Examples ofgastrosoluble polymers are gastrosoluble polyvinyl derivatives, such aspolyvinyl acetal diethyl aminoacetate, and the like, gastrosolubleacrylic acid copolymers such as methyl methacrylate-butylmethacrylate-dimethylaminoethyl methacrylate copolymer (for instance,brand name Eudragit E, Röhm), and the like, and the like. Examples ofenterosoluble polymers are enterosoluble cellulose derivatives, such ashydroxypropylmethyl cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxymethyl ethyl cellulose phthalate,carboxymethyl ethyl cellulose, and the like, enterosoluble acrylic acidcopolymers, such as methacrylic acid-methyl methacrylate copolymer (forinstance, brand name: Eudragit L100, Eudragit S, both by Röhm),methacrylic acid-ethyl acrylate copolymer (for instance, brand name ofEudragit L100-55, Eudragit L30D55, Röhm), and the like, and the like.Examples of wax-like substances are solid oils and fats, such ashydrogenated castor oil, hydrogenated coconut oil, tallow, and the like,higher fatty acids, such as stearic acid, lauric acid, myristic acid,palmitic acid, and the like, and higher alcohols, such as cetyl alcohol,stearyl alcohol, and the like. Of these, methacrylic acid-ethyl acrylatecopolymer is preferred for providing enterosolubility and pH-independentwater-insoluble polymer, particularly ethyl cellulose, is preferred forproviding sustained release whereby a drug is released gradually. One oran appropriate combination of two or more of these polymer substancescan be used for the goal of controlled dissolution.

Furthermore, plasticizer can also be added as needed. Examples of thisplasticizer are triacetin, triethyl citrate, dibutyl sebacate,acetylated monoglyceride, ethyl acrylate-methyl methacrylate copolymerdispersion (for instance brand name: Eudragit NE30D, Röhm), and thelike, and triacetin and ethyl acrylate-methyl methacrylate copolymerdispersion are preferred.

Moreover, water-soluble polymers, saccharides, salts, and the like, canbe mixed with the above-mentioned polymer substances, such aswater-insoluble polymers, gastrosoluble polymers, enterosolublepolymers, and the like, or wax-like substances, and the like. Examplesof these substances are hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl pyrrolidone, polyvinyl alcohol, and the like, aswater-soluble polymer substances. Examples of saccharides are maltose,maltitol, and the like, and examples of salts are sodium chloride, andthe like. The amount of polymer and saccharide used here can be adjustedas needed in order to control the dissolution speed of the drug.Moreover, one or a combination of two or more of these polymers andsaccharides can be used. Incidentally, the water-soluble polymersubstances, saccharides, and salts used here are added in order toeasily control dissolution of drug from the sustained-release fineparticles, and they should be differentiated from those that are used inpreparation of the composition of the present invention.

There are no special restrictions to the “filler” used in the presentinvention as long as it is a pharmaceutically acceptable sugar or sugaralcohol. Examples of sugar or sugar alcohol are saccharides of lowmoldability disclosed in International Early Disclosure PamphletWO95/20380. Specific examples are xylitol, erythritol, glucose,mannitol, sucrose, and lactose. Of these, mannitol, lactose, anderythritol are preferred. In addition, one or a combination of two ormore of these saccharides can be used. The “saccharide of lowmoldability” here means one that, for instance, shows a tablet hardnessof less than 2 kp when 150 mg saccharide are tableted under a tabletingpressure of 10 to 50 kg/cm² using a punch with a diameter of 8 mm (referto WO95/20380 (corresponding U.S. Pat. No. 5,576,014, Japanese PatentNo. 3122141). Moreover, sugars with a high melting point and sugars witha low melting point in U.S. patent application Ser. No. 10/142,081(corresponding International Patent Application No. PCT/JP02/04481) canalso be selected.

There are no special restrictions to the saccharide with a low meltingpoint used in the present invention as long as it is pharmaceuticallyacceptable and it is a saccharide with a low melting point listed inU.S. patent application Ser. No. 10/142,081 (corresponding InternationalPatent Application No. PCT/JP02/04481) and it has a relatively lowermelting point than the drugs and saccharides with a high melting pointused in the present invention, but a saccharide with a melting point ofapproximately 80 to approximately 180° C. is preferred and a saccharide[with a melting point] of approximately 90 to 150° C. is furtherpreferred. Examples of this saccharide are glucose (monohydrate, meltingpoint of 83° C.), xylitol (melting point of 93° C.), trehalose(dihydrate, melting point of 97° C.), sorbitol (hydrate, melting pointof a little less than 100° C.), maltose (melting point of 102° C.),sorbitol (melting point of 110° C.), erythritol (melting point of 122°C.), glucose (melting point of 146° C.), maltitol (melting point of 150°C.), mannitol (melting point of 166° C.), sucrose (melting point ofapproximately 170° C.), and the like. One or two or more saccharidesselected from the group consisting of these can be used. Of thesesaccharides, one or two or more saccharides selected from glucose,xylitol, trehalose, sorbitol, maltose, erythritol, maltitol, and theirhydrates are preferred. Trehalose, maltose, erythritol, or maltitol,particularly trehalose and/or erythritol, are ideal because thesesaccharides themselves are only slightly moisture-absorbing andtherefore are easy to handle. One or a combination of two ore more ofthese saccharides can be used. These saccharides also can be used as ahydrate. When the hydrate and anhydride of the saccharide have differentmelting points, the heating temperature should be set accordingly asneeded.

The “saccharide with a high melting point” used in the present inventionis a saccharide with a high melting point listed in U.S. patentapplication Ser. No. 10/142,081 (corresponding Patent Application No.PCT/JP02/04481). It is a saccharide whose melting point temperaturedifference from the saccharide with a low melting point used in thepresent invention is 10° C. or higher, further preferably, a saccharidewith a melting point temperature difference of 20° C. or higher. Takinginto consideration the difference between the temperature at which theheating device is set and the temperature of the tablet, which is theobject to be heated, it is preferred that saccharides with a greaterdifference between their melting points be selected. Specifically,xylitol (melting point of 93° C.), trehalose (dihydrate, melting pointof 97° C.), sorbitol (hydrate, melting point of a little less than 100°C.), maltose (melting point of 102° C.), sorbitol (melting point of 110°C.), erythritol (melting point of 122° C.), glucose (melting point of146° C.), maltitol (melting point of 150° C.), mannitol (melting pointof 166° C.), sucrose (melting point of approximately 170° C.), lactose(melting point of 202° C.), and the like, are given. One or two or moresaccharides selected from the group consisting of these can be used.Illustration of saccharides with a high melting point virtuallyduplicates the saccharides with a low melting point, but because a “asaccharide with a high melting point” is selected in terms of a relativerelationship with the saccharide with a low melting point, the samesaccharides are not selected. The “saccharides with a high meltingpoint” and “saccharides with a low melting point” of the presentinvention are selected as needed taking into consideration the chemicalproperties of the drug that will be used, that is, stability of the drugwith respect to temperature. When the relationship between the“saccharide with a high melting point” and the “saccharide with a lowmelting point” is described in specific terms, xylitol, trehalose,sorbitol, erythritol, glucose, maltitol, mannitol, sucrose, lactose, andtheir hydrates can be used as the “saccharide with a high melting point”when glucose (monohydrate, melting point of 83° C.) is used as the“saccharide with a low melting point” that is used in the presentinvention. Moreover, sorbitol, erythritol, glucose, maltitol, mannitol,sucrose, lactose, and their hydrates can be used as the “saccharide witha high melting point” when xylitol (melting point of 93° C.) ortrehalose (dihydrate, 97° C.) is used as the “saccharide with a lowmelting point” that is used in the present invention. Glucose, maltitol,mannitol, sucrose or lactose can be used as “the saccharide with a highmelting point” when erythritol (melting point of 122° C.) is used as the“saccharide with a low melting point” that is used in the presentinvention. Furthermore, mannitol, sucrose or lactose can be used as the“saccharide with a high melting point” when maltitol (melting point of150° C.) is used as the “saccharide with a low melting point” in thepresent invention. In addition, lactose can be used as the “saccharidewith a high melting point” when sucrose (melting point of approximately170° C.) is used as the “saccharide with a low melting point” in thepresent invention. The “saccharide with a high melting point” isselected as described, as necessary in accordance with the type ofsaccharide used in the present invention. When selecting the saccharidesso that there is a greater difference between their melting points, the“saccharide with a high melting point” is preferably one or two or moresaccharides selected from the group consisting of glucose, maltitol,mannitol, sucrose and lactose, and further preferably mannitol, sucrose,and lactose. These are used in the appropriate amounts of one or amixture of two or more as needed.

The saccharides of high moldability listed in International EarlyDisclosure Pamphlet WO95/20380, the saccharides with a low melting pointlisted in U.S. patent application Ser. No. 10/142,081 (correspondingInternational Patent Application PCT/JP02/04481), or water-solublepolymer substances are selected as the “binder for quick-disintegratingtablets in the buccal cavity” used in the present invention. Forinstance, maltose (preferably malt syrup powder (maltose content of 83%or higher)), trehalose, sorbitol, or maltitol are given as saccharidesof high moldability, and maltose and trehalose are preferred. The“saccharide of high moldability” here means one that shows a tablethardness of 2 kp or more when 150 mg saccharide are tableted under atableting pressure of 10 to 50 kg/cm² using a punch with a diameter of 8mm (refer to WO 95/20380 (corresponding U.S. Pat. No. 5,576,014,Japanese Patent No. 3122141). The above-mentioned saccharides with a lowmelting point are given as saccharides with a low melting point.Moreover, hydroxypropyl cellulose, hydroxypropylmethyl cellulose,polyvinyl pyrrolidone, copolyvidone, polyvinyl alcohol, and the like,are given as water-soluble polymer substances. One or a combination oftwo or more “binder for quick-disintegrating tablets in the buccalcavity” can be used. Hydroxypropyl cellulose, hydroxypropylmethylcellulose, or copolyvidone with low hygroscopicity are preferred takinginto consideration the environment during storage as a starting materialand a pharmaceutical preparation, and copolyvidone is ideal.

In addition, the “binder for quick-disintegrating tablets in the buccalcavity” of the present invention can be one or two or more selected fromthe group consisting of “saccharides of high moldability,” “saccharideswith a low melting point,” and “water-soluble polymer substances.”

I. “Filler”: saccharide of low moldability, “binder forquick-disintegrating tablets in the buccal cavity”: saccharide of highmoldability, or water-soluble polymer substance,

II. “Filler”: saccharide with a high melting point, “binder forquick-disintegrating tablets in the buccal cavity”: saccharide with alow melting point,

III. “Filler”: saccharide with a high melting point, “binder forquick-disintegrating tablets in the buccal cavity”: saccharide with alow melting point, and water-soluble polymer substance, and

IV. “Filler”: saccharide with a high melting point and saccharide with alow melting point, “binder for quick-disintegrating tablets in thebuccal cavity”: water-soluble polymer substance or saccharide of highmoldability are given as specific embodiments of the present inventionrelating to selection of the above-mentioned “filler” and “binder forquick-disintegrating tablets in the buccal cavity.” As a specificillustration of IV, it is preferred that erythritol is selected as the“saccharide with a low melting point,” lactose and/or mannitol areselected as the “saccharide with a high melting point,” and maltitol isfurther selected as the binder for quick-disintegrating tablets in thebuccal cavity (“saccharide of high moldability”), or that erythritol isselected as the “saccharide with a low melting point,” lactose and/ormannitol are selected as the “saccharide with a high melting point,” andcopolyvidone is further selected as the binder for quick-disintegratingtablets in the buccal cavity (“water-soluble polymer”).

The amount of “filler” used in the present invention is adjusted asneeded in accordance with the dose of the drug and/or the size of thetablets. This amount added is adjusted as needed by increasing theamount of “filler” used in the present invention when the dose of drugis small and by reducing the amount of “filler” used in the presentinvention when the dose of drug is large, and the like, to obtaintablets of the desired size. It is usually preferably 20 to 1,000 mg,further preferably 50 to 500 mg, even more preferably 100 to 400 mg, pertablet. There is a chance that thorough granulation cannot be realizedif the amount of filler added is less than 20 mg. Moreover, the amountof filler to the amount of saliva in the buccal cavity will be too greatwhen [the amount of filler added] is more than 1,000 mg, and anuncomfortable feeling will be produced when it is in the mouth.

The amount of “binder for quick-disintegrating tablets in the buccalcavity” that is used in the present invention is usually preferably 0.5to 50 w/w %, further preferably 1 to 30 w/w %, even more preferably 1 to20 w/w %, per weight of “filler” used in the present invention. If it isless than 0.5 w/w % per the weight of “filler,” there is a chance thatfunction as a binder will not be realized in full. Moreover, if there ismore than 50 w/w % per the weight of “filler,” there is a possibilitythat many problems, including delayed disintegration, and the like, willoccur and good properties will not be obtained when used as aquick-disintegrating tablet in the buccal cavity. Although the mixtureratio of “sustained-release fine particles,” “filler,” and “binder forquick-disintegrating tablets in the buccal cavity” should not bedefinitively set forth by their percentages, when an illustration isgiven, their respective mixture ratio is preferably 1 to 50%, 20 to 98%,and 1 to 30%, more preferably 1 to 20%, 60 to 98%, and 1 to 20%.

In addition to the “filler” and “binder for quick-disintegrating tabletsin the buccal cavity” that are used in the present invention, it ispossible to add a variety of additives that are pharmaceuticallyacceptable and are used as additives. These additives can be mixed withthe filler when the sustained-release fine particles are granulated, orthey can be used as a mixture with the composition of the presentinvention when tablets are made. Examples of these additives aredisintegrants, sour flavorings, foaming agents, artificial sweeteners,fragrances, lubricants, coloring agents, stabilizers, and the like. Oneor a combination of two or more of these additives can be used.Moreover, there are no particular restrictions to the amount added aslong as it is the amount normally pharmaceutically used by persons inthe field and it is within a range with which the results of the presentinvention are not compromised.

Examples of disintegrants are starches, such as corn starch, and thelike, carmellose calcium, partially alpha-converted starch, crospovidon,lower-substituted hydroxypropyl cellulose, and the like. Examples ofsour flavoring are citric acid, tartaric acid, malic acid, and the like.Examples of foaming agents are sodium bicarbonate, and the like.Examples of artificial sweeteners are saccharine sodium, glycyrrhizinatedipotassium, aspartame, stevia, sormatin, and the like. Examples offragrances are lemon, lemon-lime, orange, menthol, and the like.Examples of lubricants are magnesium stearate, calcium stearate, sucrosefatty acid ester, polyethylene glycol, talc, stearic acid, and the like.Examples of coloring agents are food coloring, such as yellow food dyeNo. 5, red food dye No. 2, blue food dye No. 2, and the like; food lakecoloring; iron oxide red, and the like. Stabilizers are selected by drugafter performing various tests. One or a combination of two or more ofthese additives can be added in an appropriate amount as needed.

The processes of the method of manufacturing the composition comprisingsustained-release fine particles of the present invention, particularlythe manufacturing conditions, and the like, will now be described indetail:

The method of manufacturing the composition comprising sustained-releasefine particles for quick-disintegrating tablets in the buccal cavity ofthe present invention will now be described using (a) the process ofmanufacturing sustained-release fine particles comprising the amount ofdrug that is effective in terms of treatment or prevention and withwhich the speed of dissolution of this drug is controlled and (b) theprocess whereby “sustained-release fine particles” and “filler” aregranulated with “binder for quick-disintegrating tablets in the buccalcavity.”

Process (a): Process of Manufacture of Sustained-Release Fine Particles

The sustained-release fine particles are made by conventional methods,as previously mentioned. There are no particular restrictions to thismethod and it can be selected as needed as long as it is one with whichthe goal of controlled dissolution is obtained. For instance, drug islayered and coated on commercial crystalline cellulose particles,crystalline lactose, granular sugar, sodium chloride, silicon dioxide,and the like, using a binder such as hydroxypropylmethyl cellulose, andthe like, and then a polymer substance, such as water-insoluble polymersubstance, gastrosoluble polymer substance, enterosoluble polymersubstance, wax-like substance, and the like, is further coated on thisto make sustained-release fine particles. It is also possible to layerand coat a polymer substance, such as water-insoluble polymer substance,gastrosoluble polymer substance, enterosoluble polymer substance,wax-like substance, and the like, together with drug on commercialcrystalline cellulose particles, crystalline lactose, granular sugar,sodium chloride, silicon dioxide, and the like to make sustained-releasefine particles. Sustained-release fine particles are also made by theagitation granulation method or tumbling fluidized granulation methodafter adding a solution of polymer substance to drug andmicrocrystalline cellulose. The above-mentioned coating can be furtherperformed on these sustained-release fine particles, and they can begiven enterosoluble function by coating with enterosoluble polymer baseas necessary. A fluidized bed granulator, and the like, for instance, isselected for coating. Temperature, and further, the spraying liquidvolume, spraying air volume, and the like, are set so that the producttemperature is approximately 40° C. to approximately 60° C. in the caseof coating using water and at approximately 30° C. to approximately 60°C. when an organic solvent is used. The concentration of drug,percentage and amount of polymer substance, and the like, used for thecoating can be adjusted as needed in accordance with the desired speedof dissolution.

Process (b): Granulation Process

There are no special restrictions to the granulation method of thepresent invention as long as it is one with which the sustained-releasefine particles have been granulated with “filler” and “binder forquick-disintegrating tablets in the buccal cavity”. For example,fluidized bed granulation, agitation granulation, tumbling granulation,and the like, can be selected as this granulation method. Of these, thefluidized bed granulation method is preferred in terms of productivity.The method whereby a solution of the “binder for quick-disintegratingtablets in the buccal cavity” that is used in the present inventiondissolved and/or suspended in a pharmaceutically acceptable solvent issprayed onto a mixture of sustained-release fine particles and “filler”to make granules and prepare the “composition” can be selected for thefluidized bed granulation method. The sustained-release fine particlesshould be covered with “filler” at this time. The manufacture conditionsare preferably, for instance, a product temperature of approximately 25°C. to approximately 40° C. and a water content of approximately 0.2 toapproximately 5%. Moreover, granulation by intermittent spraying ispreferred. “Intermittent spraying” means interrupted spraying and is themethod of spraying for granulation whereby, for instance, cycles ofspraying for 10 seconds following by drying for 30 seconds, and thelike, are repeated. Moreover, this cycle can be set as needed formanufacture. In addition, the spray time-dry time can be selectedappropriately. It is also possible to granulate after adding theabove-mentioned additives as needed.

The “filler” can be a commercial product used as is. When mean particlediameter of the “filler” is larger than the mean particle diameter ofthe sustained-release fine particles, it is preferred that the “filler”be pulverized using an appropriate pulverizing device, such as hammermill, sample mill, pin mill, and the like, in order to facilitategranulation with the sustained-release particles. It is preferred thatthe “binder for quick-disintegrating tablets in the buccal cavity” bedissolved in water to obtain a solution when it is a saccharide of highmoldability. This liquid concentration should be, for instance, 10 to 40w/w %, more preferably 20 to 30 w/w %, in order to maximize bindingability of the binder for quick-disintegrating tablets in the buccalcavity. If liquid concentration is lower than 10 w/w %, the liquidvolume will be too great and the procedure will take more time, while ifthe liquid concentration is higher than 40 w/w %, the procedure will becompleted in a shorter amount of time and it will therefore be difficultto maintain the spraying time-drying time cycle.

Moreover, the composition comprising sustained-release fine particles ofthe present invention can be used in the quick-disintegrating tablets inthe buccal cavity, and this method comprises (c): the process of makingtablets by tableting the composition obtained in process (b) and (d):the process of humidifying and drying the tablets obtained in process(c) as necessary. Furthermore, when the above-mentioned saccharide witha high melting point and saccharide with a low melting point have beenselected for the composition, it is possible to select the methodconsisting of process (d′): the process of heating the tablets obtainedby process (c), and (e): the process of cooling after process (d′).Process (d) can also be performed after processes (d′) and (e).

Process (c): Tableting Process

“Tableting” is performed by conventional methods. There are noparticular restrictions as long as it is a method by which the shape ofa tablet is obtained under at least the minimum pressure necessary toretain the shape of a tablet. This “tableting” can be performed using,for instance, an ordinary tableting machine, such as a single tabletingmachine or a rotary tableting machine, and the like, after adding thenecessary additives, beginning with lubricant such as magnesiumstearate, and the like, to the above-mentioned “composition.” Moreover,the above-mentioned “composition” can also be made into tablets using anexternal-lubricating tableting machine. Tableting pressure of usuallyapproximately 25 to approximately 800 kg/punch is preferred,approximately 50 to approximately 500 kg/punch is further preferred,approximately 50 to approximately 300 kg/punch is most preferred.

Process (d): Humidifying and Drying Process

When the saccharide that is the “binder for quick-disintegrating tabletsin the buccal cavity” used in the granulation process becomes amorphousand there is a reduction in strength of the tablet obtained by thetableting process due to absorption of moisture, that is, when the“binder for quick-disintegrating tablets in the buccal cavity” used inthe present invention is a saccharide of high moldability and maltose,sorbitol, or trehalose is used, it is preferred that the followingprocess of humidifying and drying be used: “Humidifying” is performed incombination with the drying process, which is the process that followsthe humidifying process. There are no special restrictions to the methodas long as it is one with which the saccharide of the “binder forquick-disintegrating tablets of the buccal cavity” used in the presentinvention crystallizes from amorphous substance. The conditions of this“humidifying” are determined from the apparent critical relativehumidity of the mixture comprising sustained-release fine particlecontaining drug, “binder for quick-disintegrating tablets in the buccalcavity” used in the present invention, and “filler.” Humidifying isusually performed to at least the critical relative humidity of thismixture. For instance, approximately 30 to approximately 100 RH % ispreferred and approximately 50 to approximately 90 RH % is furtherpreferred as the humidity. Approximately 15 to approximately 50° C. ispreferred and approximately 20 to approximately 40° C. is furtherpreferred as the temperature at this time. One to 48 hours is preferredand 12 to 24 hours is further preferred as the humidifying time.

There are no particular restrictions to the “drying” as long as it is amethod by which the moisture that has been absorbed by humidifying iseliminated. Usually approximately 10 to approximately 100° C. ispreferred, approximately 20 to approximately 60° C. is furtherpreferred, and approximately 25 to approximately 40° C. is mostpreferred as the “drying” conditions. Thirty minutes to 10 hours ispreferred and 1 to 4 hours is further preferred as the drying time.

Process (d′): Heating Process

The “heating” in the present invention is performed by conventionalmethods, and there are no special restrictions as long as it is a methodwhereby the molded article obtained by process (c) can be brought to atemperature that is at least the melting point of the above-mentioned“saccharide with a low melting point.” Said “heating” process can beperformed, for instance, using a ventilation oven. Temperatureconditions are selected as needed depending on the type of “saccharidewith a low melting point”, and there are no particular restrictions aslong as it is the melting point of the “saccharide with a low meltingpoint” used in the present invention or higher and the melting point ofthe “saccharide with a high melting point” or lower. When the“saccharide with a low melting point” used in the present invention isused, it is approximately 80 to approximately 180° C., preferablyapproximately 90 to approximately 150° C. Time conditions are selectedas needed depending on the type of saccharide that is used, the desiredtablet strength, disintegration performance in the buccal cavity, andthe like, but it is usually 0.5 to 120 minutes, preferably 1 to 60minutes, further preferably 2 to 30 minutes.

Process (e): Cooling Process

The “cooling” in the present invention is performed by conventionalmethods, and there are no particular restrictions as long as it is amethod whereby the saccharide with a low melting point that is used inthe present invention is solidified after melting. Said “cooling” can beperformed by, for instance, being set aside at room temperature or beingstored in a low-temperature atmosphere, such as a refrigerator, and thelike.

Next, an example of the method of manufacturing the compositioncomprising sustained-release fine particles for quick-disintegratingtablets in the buccal cavity of the present invention is given below:First, drug is layered and coated on commercial crystalline celluloseparticles (for instance, Celphere 102) using an appropriate binder (forinstance, hydroxypropylmethyl cellulose) with a fluidized bedgranulator, and the like. Sustained-release fine particles are obtainedby further coating a mixture of water-insoluble polymer substance (forinstance, ethyl cellulose) and water-soluble polymer (for instance,hydroxypropylmethyl cellulose) as needed using a fluidized bedgranulator, and the like, in order to obtain the desired dissolution.Then these fine particles and sugar (for instance, mannitol) areintermittently granulated (for instance, cycle of spraying for 10seconds and then drying for 30 seconds) with the binder forquick-disintegrating tablets in the buccal cavity (for instance,maltose) using a fluidized bed granulator, and the like, to obtain thecomposition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity of the presentinvention.

Quick-disintegrating tablets in the buccal cavity comprisingsustained-release fine particles can be prepared by adding additives asnecessary, for example, an appropriate lubricant such as magnesiumstearate, and the like, to the composition comprising sustained-releasefine particles used for quick-disintegrating tablets in the buccalcavity of the present invention and making tablets using a tabletingmachine.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is the results of dissolution experiments with JapanPharmacopoeia 1st Fluid for Disintegration Tests of the tablets andsustained-release fine particles of Example 1.

FIG. 2 is the results of dissolution experiments with JapanPharmacopoeia 2nd Fluid for Disintegration Tests of the tablets andsustained-release fine particles of Example 1.

FIG. 3 is the results of dissolution experiments with JapanPharmacopoeia 1st Fluid for Disintegration Tests of the tablets andsustained-release fine particles of Comparative Examples 1 and 2.

DETAILED DESCRIPTION OF THE INVENTION

The present invention will be further described below with examples, butinterpretation of the present invention is not limited to theseexamples.

Methods of Evaluating Composition Comprising Sustained-Release FineParticles

[Determination of Particle Diameter Distribution of Sustained-ReleaseFine Particles and Composition Comprising Sustained-Release FineParticles]

Particle diameter was determined with a sieve-type particle diameterdistribution gauge (Seishin Enterprise Co., Ltd. Robot Sifter) usingsieves with openings of 30, 42, 60, 80, 100, 150, 200, and 250 mesh.

[Determination of Quantitative Ratio by Particle Diameter of CompositionComprising Sustained-Release Fine Particles]

Composition remaining on sieves with each of the above-mentioned openingsizes is recovered and the quantitative amount of each fraction isdetermined. Assuming that the total quantitative amount is 100%, theratio accounted for by the quantitative amount on each sieve iscalculated and serves as the quantitative ratio by particle diameter.Moreover, the quantitative distribution by particle diameter wasobtained by arranging the quantitative ratio by particle diameter in theorder of the opening size of each sieve. Incidentally, any method can beused to determine the quantitative amount as long as the drug that iscontained is thoroughly recovered from the composition, anddetermination is performed by the determination method suitable for eachdrug.

[Ratio of Ungranulated Sustained-Release Fine Particles]

The particle diameter distribution of sustained-release fine particlesand the quantitative distribution by particle diameter of thecomposition comprising sustained-release fine particles is determinedand calculated by the following formula:Ratio of ungranulated sustained release fine particles (%)=G ₁+Σ(G_(i+1)−(P _(i) −G _(i)))

Here, the estimation of Σ is obtained by calculation from i=1 andestimating the value up to the point before (G_(i+1)−(P_(i)−G_(i)))becomes negative.

P₁: sustained-release fine particle ratio on sieve with smallest openingsize within the particle diameter distribution of the sustained-releasefine particles (with the exception of that where it is 0%). That is, itis 15.0% on 150 mesh in the following examples.

P₂: sustained-release fine particle ratio on sieve with second smallestopening size within particle diameter distribution of sustained-releasefine particles (with the exception of that where it is 0%). That is, itis 70.6% on 100 mesh in the following examples. The third, fourth and soon is referred to as P₃, P₄ and they are as a whole represented asP_(i).

G₁: value of quantitative ratio by particle diameter distribution ofcomposition on sieve with the same opening size as P₁. That is, it is2.5% on 150 mesh in the following examples.

G₂: value of quantitative ratio by particle diameter distribution ofcomposition on sieve with same opening size as P₂. That is, it is 14.3%on 100 mesh in the following examples. The third, fourth, and so on arereferred to as G₃, G₄, and so on, and they are as a whole represented asG_(i).

For instance, if the determination results are as follows: Particlediameter Quantitative distribution distribution of sustained- byparticle diameter of release fine particles Example 1 composition  30Mesh on (%) 0 19.0  42 Mesh on (%) 0 22.4  60 Mesh on (%) 0 23.5  80Mesh on (%) 14.4 18.2 100 Mesh on (%) 70.6 14.3 150 Mesh on (%) 15.0 2.5200 Mesh on (%) 0 0 200 Mesh pass (%) 0 0the ratio (%) of ungranulated sustained-release fine particles

$\begin{matrix}{= {G_{1} + {\Sigma\left( {G_{i + 1} - \left( {P_{i} - G_{i}} \right)} \right)}}} \\{= {G_{1} + \left( {G_{2} - \left( {P_{1} - G_{1}} \right)} \right) + \left( {G_{3} - \left( {P_{2} - G_{2}} \right)} \right) + \ldots}} \\{= {2.5 + \left( {14.3 - \left( {15 - 2.5} \right)} \right) + \left( {18.2 - \left( {70.6 - 14.3} \right)} \right) + \left( {23.5 - \left( {14.4 - 18.2} \right)} \right)}} \\{= {2.5 + \left( {+ 1.8} \right) + \left( {- 38.1} \right)}}\end{matrix}$

If the figures in parentheses are negative, it means that thesustained-release fine particles have a particle diameter that is atleast 1 rank larger because of granulation. Therefore, there is nofurther estimation performed and $\begin{matrix}{= {2.5 + \left( {+ 1.8} \right)}} \\{= 4.3}\end{matrix}$Methods for Evaluating Quick-Disintegrating Tablets in the Buccal Cavity

[Hardness tests] Determinations were performed using a Schleunigertablet hardness meter (Schleuniger Co., Ltd.). The tests were performedwith 5 tablets and the mean is shown. Tablet hardness is represented bythe force needed to crush the tablet (units kp). A larger numberindicates a stronger tablet.

[Friability] Determinations were performed using a friability tester(model PTFR-A, Pharma Test Co.) The friability is found using 6 gtablets. It is represented by the percentage weight loss of a tabletafter being turned 100 times at a turning speed of 25 rpm. A smallervalue indicates a stronger tablet surface.

[Disintegration in buccal cavity tests] Healthy adult males placed thetablet of the present invention in their buccal cavity without any waterin the buccal cavity and the time until the tablet was completelydisintegrated and dissolved by saliva only was determined.

[Content uniformity tests] The drug content of each of 10 tablets wasquantitatively determined and is represented as the coefficient ofvariation (CV %) of the amount of drug from the above-mentioned formula.

[Dissolution tests] Tests were conducted by Dissolution Test Method No.2 in accordance with Revised Version 12 of the Japanese Pharmacopoeia.

EXAMPLE 1

Eighty grams tamsulosin hydrochloride and 80 g hydroxypropylmethylcellulose (TC5E, Shin-Etsu Chemical Co., Ltd.) were dissolved in amixture of 304 g purified water and 2,736 g methanol. Four-thousandgrams Celphere 102 (brand name, Asahi Kasei, mean particle diameter ofapproximately 127 μm, particle diameter of approximately 50 toapproximately 150 μm) were introduced to a fluidized bed granulator(Freund Industries, FLO-5) and coated with this solution by the sidespraying method (spraying liquid volume 100 g/min, spraying air pressure4 kg/cm², product temperature 40° C., inlet temperature 80° C.) toobtain tamsulosin hydrochloride particles. Separately, 533 g ethylcellulose (Nissin Chemistry Co.) and 187 g hydroxypropylmethyl cellulose(TC5E, brand name, Shin-Etsu Chemical Co., Ltd.) were dissolved in amixture of 698 g purified water and 22,582 g methanol. Four thousandgrams tamsulosin hydrochloride particles were introduced to a fluidizedbed granulator (Freund Industries, FLO-5) and coated with this solutionby side spraying (spraying liquid volume of 40 g/min, spraying airpressure of 4 kg/cm², product temperature of 50° C., inlet temperatureof 60° C.) to obtain sustained-release fine particles. Four-thousandgrams of these sustained-release fine particles were introduced to afluidized bed granulator (Freund Industries, FLO-5) and coated with amixture of 2,000 g Aquacoat (brand name, Asahi Kasei), 4,000 g EudragitL30D55 (brand name, Röhm), 667 g Eudragit NE30D (brand name, Röhm), and6,667 g purified water (spraying liquid volume of 40 g/min, spraying airpressure of 4 kg/cm², product temperature of 40° C., inlet temperatureof 60° C.) to obtain enteric sustained-release fine particles.

Then 368 g of these enteric sustained-release fine particles, 2,560 gmannitol (Towa Kasei Co., Ltd.), and 640 g lactose (Domomilk) weregranulated (spraying liquid volume 200 g/min, spraying air pressure of1.5 kg/cm², product temperature of 29° C., inlet temperature of 80° C.,spraying cycle of 10 seconds spraying to 30 seconds drying) with anaqueous 40% w/w solution containing 400 g maltose (Hayashibara Co.,Ltd., brand name: Sunmalt S) in a fluidized bed granulator (FreundIndustries, FLO-5) to obtain the composition of the present invention.

After further mixing 32 g calcium stearate with the composition that wasobtained, 200 mg tablets containing 0.2 mg tamsulosin hydrochloride pertablet were made under a tableting pressure of 100 kg/punch and aninitial hardness of 1.0 kp using a rotary tableting machine. Next, thesetablets were kept for 18 hours while heating and humidifying at 25°C./75% RH using a thermostatic chamber at constant humidity (TabaiespecCo., Ltd., PR-35C). Then they were dried for 3 hours at 30° C. and 40%RH. The tablets that were obtained showed a hardness of 5.9 kp (n=5),friability of 0.8% (100 rounds) and disintegration time in the buccalcavity of 20 seconds (n=3). Moreover, as a result of evaluatinguniformity of content, CV %=2.1%, proving that there is good uniformityof content.

COMPARATIVE EXAMPLE 1

First, 319.3 g mannitol (Towa Kasei Co., Ltd) and 79.7 g lactose(Domomilk) were granulated (spraying liquid volume 10 g/min, sprayingair pressure 1.5 kg/cm², product temperature 30° C., inlet temperature60° C., spraying cycle: continuous spraying) with an aqueous 20% w/wsolution containing 50 g maltose (Hayashibara Co., Ltd., brand name:Sunmalt S) in a fluidized bed granulator (Freund Industries, uni-glatt).After mixing 45.2 g of the enteric sustained-release fine particlesprepared in Example 1 and 5 g calcium stearate with the product that wasobtained, 200 mg tablets containing 0.2 mg tamsulosin hydrochloride pertablet were made under a tableting pressure of 93 kg/punch and aninitial hardness of 1.0 kp using a rotary tableting machine. Next, thesetablets were kept for 18 hours while heating and humidifying at 25°C./75% RH using a thermostatic chamber at constant humidity (TabaiespecCo., Ltd., PR-35C). Then they were dried for 3 hours at 30° C. and 40%RH. The tablets that were obtained had a hardness of 4.1 kp (n=5) and adisintegration time in the buccal cavity of 15 seconds (n=3). Moreover,the results of evaluating uniformity of content were CV %=5.6%, with thetablets having inferior uniformity of content.

COMPARATIVE EXAMPLE 2

First, 45.2 g enteric sustained-release fine particles prepared inExample 1, 319.3 g mannitol (Towa Kasei Co., Ltd.), and 79.7 g lactose(Domomilk) were granulated (spraying liquid volume 10 g/min, sprayingair pressure 1.5 kg/cm², product temperature 30° C., inlet temperature60° C., spraying cycle: continuous spraying) with an aqueous 20% w/wsolution containing 50 g maltose (Hayashibara Co., Ltd., brand name:Sunmalt S) in a fluidized bed granulator (Freund Industries, uni-glatt).After mixing 5 g calcium stearate with the product that was obtained,200 mg tablets containing 0.2 mg tamsulosin hydrochloride per tabletwere made under a tableting pressure of 96 kg/punch and an initialhardness of 1.0 kp using a rotary tableting machine. Next, these tabletswere kept for 18 hours while heating and humidifying at 25° C./75% RHusing a thermostatic chamber at constant humidity (Tabaiespec Co., Ltd.,PR-35C). Then they were dried for 3 hours at 30° C. and 40% RH. Thetablets that were obtained had a hardness of 3.7 kp (n=5) and adisintegration time in the buccal cavity of 15 seconds (n=3). Moreover,the results of evaluating uniformity of content were CV %=4.0%, with thetablets having inferior uniformity of content.

Experiment 1 (Quantitative Amount by Particle Diameter Distribution)

The particle diameter distribution of the sustained-release fineparticles obtained in Example 1 and the particle diameter distributionas well as quantitative distribution by particle diameter of thecomposition prepared in Examples 1 and 2 (Table 1) as well as theproduct prepared in Comparative Examples 1 and 2 (Table 2) are showntogether. TABLE 1 Particle diameter distribution of sustained releasefine particles and particle diameter distribution and quantitativedistribution by particle diameter of compositions of Examples 1 and 2Particle Quantitative Quantitative diameter Particle distribution byParticle distribution distribution diameter particle diameter byparticle of sustained- distribution diameter of distribution diameter ofrelease fine of Example 1 Example 1 of Example 2 Example 2 particlescomposition composition composition composition Mean particle 165 393 —204 — diameter (μm)  30 Mesh on (%) 0 26.9 19.0 1.5 1.1  42 Mesh on (%)0 29.7 22.4 5.1 6.2  60 Mesh on (%) 0 23.8 23.5 23.1 27.2  80 Mesh on(%) 14.4 9.8 18.2 31.5 43.4 100 Mesh on (%) 70.6 2.8 14.3 15.2 17.6 150Mesh on (%) 15.0 3.1 2.5 16.1 4.3 200 Mesh on (%) 0 1.5 0 5.1 0 200 Meshpass (%) 0 2.5 0 2.5 0 Ratio of ungranulated — — 4.3 — 11.2 product (%)

TABLE 2 Particle diameter distribution of sustained-release fineparticles and particle diameter distribution as well as quantitativedistribution by particle diameter of products in Comparative Examples 1and 2 Particle Quantitative Particle Quantitative Particle diameterdistribution by diameter distribution diameter distribution particledistribution by particle distribution of diameter of of diameter of ofsustained- Comparative Comparative Comparative Comparative release fineExample 1 Example 1 Example 2 Example 2 particles product productproduct product Mean particle diameter 165 179 — 196 — (μm)  30 Mesh on(%) 0 4.7 0 3.1 2.1  42 Mesh on (%) 0 8.0 0 11.3 10.3  60 Mesh on (%) 013.8 0 17.8 19.3  80 Mesh on (%) 14.4 23.6 14.2 23.4 42.2 100 Mesh on(%) 70.6 18.9 70.9 12.8 21.2 150 Mesh on (%) 15.0 17.8 14.4 13.8 4.9 200Mesh on (%) 0 8.4 0 8.8 0 200 Mesh pass (%) 0 4.9 0 9.0 0 Ratio ofungranulated — — 99.2 — 16.0 product (%)

The majority of sustained-release fine particles are within 80 to 100mesh and the results of quantitative ratio by particle diameterdistribution in Examples 1 and 2 confirm that most of thesustained-release fine particles are coated with filler by granulationand distribution of composition comprising sustained-release fineparticles shifts in the direction of a large particle diameter. On theother hand, with respect to distribution of the product in ComparativeExample 2, it is confirmed that apparent particle diameter is large, butthe quantitative ratio by particle diameter does not necessarilycoincide with distribution of the product. In particular, thequantitative ratio for 80 to 100 mesh, under which the ungranulatedsustained-release particles fall, is 20% or higher and it was observedthere are many sustained-release particles that are not granulated.

Separately, many sustained-release fine particles that were notgranulated were observed in the 80-150 mesh part of the product ofComparative Example 2 as a result of microscopic observation ofcomposition and product. On the other hand, almost no ungranulatedsustained-release fine particles were observed with the composition ofExample 1. Thus, finding that support the above-mentioned data wereobtained even by microscopic observation. Consequently, these resultsconfirm that the sustained-release fine particles were thoroughlygranulated by filler in the compositions of Examples 1 and 2. Moreover,the coefficient of variation when the ratio of ungranulated product was4.3% (Example 1) and 11.2% (Example 2) was 2.2 (CV %) and 2.1 (CV %),respectively, while the coefficient of variation when the ratio ofungranulated product was 99.2% (Comparative Example 1) and 16.0%(Comparative Example 2) was 5.6 (CV %) and 4.0 (CV %), respectively.Therefore, if the ratio of ungranulated product is 16% or higher, theresults indicate that the coefficient of variation (CV %), which is anindicator of uniformity of content, is large and exceeds the allowablevalue of 3.5%.

Experiment 2 (Dissolution Experiment)

Dissolution experiments were performed on the tablets obtained inExample 1 and Comparative Examples 1 and 2 and the results were comparedwith the dissolution speed of sustained-release fine particles only. Theexperimental conditions were 100 rpm by the paddle method, and 500 mleach of Japanese Pharmacopoeia Disintegration Test Method 1^(st) fluid(pH 1.2) and 2^(nd) fluid (pH 6.8) were used as the experimental fluids.

As a result of the experiment, in the Example there was almost nodifference (difference in values after two hours of 0.7%) between thedissolution rate of the sustained-release fine particles and tablets upto two hours after starting the dissolution experiment with the testfluid having a pH of 1.2, and even with the test fluid having a pH of6.8, the difference between the dissolution rate of thesustained-release fine particles and tablet was always less than 15% at2.9%, 5.8%, and 5.1% at each dissolution time where the dissolution rateof sustained-release fine particles was 30%, 50%, and 80%, respectively,confirming that dissolution when tablets are made is not accelerated(FIGS. 1 and 2). On the other hand, acceleration of the dissolutionspeed when tablets were made was seen when compared to thesustained-release fine particles in the Comparative Examples (FIG. 3,difference between values after two hours of 15.9% and 12.8%). It wasconcluded that this was because in contrast to the fact thatsustained-release fine particles were not confirmed on the tabletsurface in Example 1, sustained-release fine particles were observed onthe tablet surface in Comparative Examples 1 and 2 and therefore, thesustained-release fine particles had been destroyed as a result ofcontact between the punch surface and sustained-release fine particles.

Consequently, it was confirmed that by means of the present invention,sustained-release fine particles are thoroughly granulated by filler andacceleration of dissolution at the time tablets are made can be avoided.

EXAMPLE 2

First, 2,609 g mannitol (Towa Kasei Co., Ltd.) and 653 g lactose(Domomilk) were pulverized with a pin mill pulverizing device (HosokawaMicron). This pulverized product and 307 g enteric sustained-releasefine particles prepared in Example 1 were granulated (spraying liquidvolume 100 g/min, spraying air pressure 1.5 kg/cm², product temperature28° C., inlet temperature 80° C., spraying cycles 20 seconds spraying-30seconds drying) with an aqueous 20% w/w solution containing 400 gmaltose (Hayashibara Co., Ltd., brand name: Sunmalt S) in a fluidizedbed granulator (Freund Industries, FLO-5) to obtain the composition ofthe present invention. After mixing 32 g calcium stearate with thiscomposition that was obtained, 120 mg tablets containing 0.1 mgtamsulosin hydrochloride per tablet were made under a tableting pressureof 100 kg/punch and initial hardness of 1.0 kp using a rotary tabletingmachine. Next, these tablets were stored for 18 hours while heating andhumidifying at 25° C./70% RH using a thermostatic chamber at constanthumidity (Tabaiespec Co., Ltd., PR-35C). Then they were dried for 3hours at 30° C. and 40% RH. The tablets that were obtained had ahardness of 5.2 kp (n=5), friability of 0.6% (100 rounds), and adisintegration time in the buccal cavity of 20 seconds (n=3). Moreover,the results of evaluating uniformity of content were CV %=2.2%,confirming that the tablets have good uniformity of content.Furthermore, as a result of performing dissolution tests on thesustained-release fine particles and the tablets that were obtained, itwas confirmed that the difference in the dissolution rate between thesustained-release fine particles and tablet was 4.7% up to two hoursafter starting the dissolution test with the test fluid having a pH of1.2, and even with the test fluid having a pH of 6.8, the difference inthe dissolution rate between the sustained-release fine particles andtablet was always less than 15% at 2.3%, 2.4%, and 1.4% at eachdissolution time where the dissolution rate of sustained release fineparticles was 30%, 50%, and 80%, respectively, indicating thatdissolution at the time of tableting is not accelerated.

Tablets were separately made with the same composition and by the samemanufacturing method as previously described. The tablets that wereobtained had a hardness of 5.6 kp (n=5), friability of 0.6% (100rounds), and dissolution time in the buccal cavity of 25 seconds (n=3).Moreover, the results of evaluating uniformity of content showed CV%=2.5%. As with the above-mentioned findings, the results of dissolutiontests did not reveal the difference between the dissolution rates of thesustained-release fine particles and the tablet. Thus, by means of thepresent invention, a composition comprising sustained-release fineparticles is prepared and therefore, uniformity of content is guaranteedas a result of preventing segregation between the sustained-release fineparticles and filler. In addition, it was confirmed that reproducibilityis obtained.

EXAMPLE 3

Three-hundred grams acetaminophen (Yoshitomi Fine Chemicals Co., Ltd.)and 60 g hydroxypropylmethyl cellulose (TC5E, Shin-Etsu Chemical Co.,Ltd.) were dissolved in a mixture of 720 g methanol and 720 gdichloromethane. Three-hundred grams Celphere 102 (brand name, AsahiKasei, mean particle diameter of approximately 127 μm, particle diameterof approximately 50 to approximately 150 μm) were introduced to afluidized bed granulator (Freund Industries, uni-glatt) and coated withthe solution by the side spraying method (spraying liquid volume 14g/min, spraying air pressure 3 kg/cm², product temperature 32° C., inlettemperature 45° C.) to obtain acetaminophen particles. Separately, 48 gethyl cellulose (Nissin Chemistry Co.) and 12 g hydroxypropylmethylcellulose (TC5E, brand name, Shin-Etsu Chemical Co., Ltd.) weredissolved in a mixture of 57 g purified water and 1,083 g methanol.Three-hundred grams acetaminophen particles were introduced to afluidized bed granulator (Freund Industries, uni-glatt) and coated withthis solution by side spraying (spraying liquid volume of 8 g/min,spraying air pressure of 3 kg/cm², product temperature of 38° C., inlettemperature of 67° C.) to obtain sustained-release fine particles.Sixty-six grams of these sustained-release fine particles and 314.25 gmannitol (Towa Kasei Co., Ltd) that had been pulverized by a pin millpulverizing device (Hosokawa Micron) were granulated (spraying liquidvolume 15 g/min, spraying air pressure of 1.1 kg/cm², producttemperature of 30° C., inlet temperature of 38° C., spraying cycle of 30seconds spraying-30 seconds drying) with an aqueous 30% w/w solutioncontaining 67.5 g maltose (Hayashibara Co., Ltd., brand name: Sunmalt S)in a fluidized bed granulator (Freund Industries, uni-glatt) to obtainthe composition of the present invention. The ratio of ungranulatedsustained-release fine particles was 0.0%. After further mixing 2.25 gmagnesium stearate with the composition that was obtained, 450 mgtablets containing 25 mg acetaminophen per tablet were made under atableting pressure of 25 kg/punch and an initial hardness of 2.0 kpusing a rotary tableting machine. Next, these tablets were kept for 24hours while heating and humidifying at 25° C./75% RH using athermostatic chamber at constant humidity (Tabaiespec Co., Ltd.,PR-35C). Then they were dried for 3 hours at 30° C. and 40% RH. Thetablets that were obtained showed a hardness of 3.5 kp (n=5) anddisintegration time in the buccal cavity of 12 seconds (n=1). Moreover,as a result of evaluating uniformity of content, CV %=1.2%, confirmingthat there is good uniformity of content. Furthermore, when dissolutionof the sustained-release fine particles and tablet was compared 2.8hours after starting dissolution tests (time when there is approximately30% dissolution of sustained-release fine particles), 5 hours after(time when there is approximately 50% dissolution of sustained-releasefine particles), and 9 hours after (time when there is approximately 80%dissolution of sustained-release fine particles) and the difference wascalculated, it was 4.9% at 2.8 hours, 4.6% at 5 hours, and 2.5% at 9hours, confirming that acceleration of dissolution of sustained-releasefine particles is prevented at any time.

EXAMPLE 4

Six-hundred grams acetaminophen (Yoshitomi Fine Chemical Co., Ltd.) and120 g hydroxypropylmethyl cellulose (TC5E, Shin-Etsu Chemical Co., Ltd.)were dissolved in a mixture of 1,440 g methanol and 1,440 gdichloromethane. Three-hundred grams sodium chloride (Shin Nihon SaltCo., Ltd., EF-70 classification, mean particle diameter of approximately67 μm, particle diameter of approximately 75 μm or smaller) wereintroduced to a fluidized bed granulator (Freund Industries, uni-glatt)and coated with this solution by the side spraying method (sprayingliquid volume 10 g/min, spraying air pressure 3 kg/cm², producttemperature 33° C., inlet temperature 55° C.) to obtain acetaminophenparticles.

Separately, 72 g ethyl cellulose (Nissin Chemistry Co.) and 8 ghydroxypropylmethyl cellulose (TC5E, brand name, Shin-Etsu Chemical Co.,Ltd.) were dissolved in a mixture of 76 g purified water and 1,444 gmethanol. Four-hundred grams acetaminophen particles were introduced toa fluidized bed granulator (Freund Industries, uni-glatt) and coatedwith this solution by side spraying (spraying liquid volume of 10 g/min,spraying air pressure of 3 kg/cm², product temperature of 39° C., inlettemperature of 70° C.) to obtain sustained-release fine particles.

Then 76.5 g of these sustained-release fine particles and 393.4 gmannitol (Towa Kasei Co., Ltd) that had been pulverized by a pin millpulverizing device (Hosokawa Micron) were granulated (spraying liquidvolume 15 g/min, spraying air pressure of 1.0 kg/cm², producttemperature of 29° C., inlet temperature of 35° C., spraying cycle of 20seconds spraying-40 seconds drying) with an aqueous 20% w/w solutioncontaining 52.5 g maltose (Hayashibara Co., Ltd., brand name: Sunmalt S)in a fluidized bed granulator (Freund Industries, uni-glatt) to obtainthe composition of the present invention. The ratio of ungranulatedsustained-release fine particles was 10.8%.

After further mixing 2.6 g magnesium stearate with the composition thatwas obtained, 350 mg tablets containing 25 mg acetaminophen per tabletwere made under a tableting pressure of 50 kg/punch and an initialhardness of 1.9 kp using a rotary tableting machine. Next, these tabletswere kept for 24 hours while heating and humidifying at 25° C./75% RHusing a thermostatic chamber at constant humidity (Tabaiespec Co., Ltd.,PR-35C). Then they were dried for 3 hours at 30° C. and 40% RH. Thetablets that were obtained showed a hardness of 4.8 kp (n=5), friabilityof 1.23% (100 rounds), and disintegration time in the buccal cavity of13 seconds (n=1). Moreover, as a result of evaluating uniformity ofcontent, CV %=2.4%, confirming that there is good uniformity of content.Furthermore, when dissolution of the sustained-release fine particlesand tablet was compared 2.8 hours after starting dissolution tests (timewhen there is approximately 30% dissolution of sustained-release fineparticles), 5 hours after (time when there is approximately 50%dissolution of sustained-release fine particles), and 9.5 hours after(time when there is approximately 80% dissolution of sustained-releasefine particles) and the difference was calculated, it was 5.5% at 2.8hours, 3.5% sustained-release fine particles [sic] at 5 hours, and 3.1%at 9.5 hours, confirming that acceleration of dissolution ofsustained-release fine particles is prevented at any time.

EXAMPLE 5

First, 1,200 g acetaminophen and 120 g hydroxypropylmethyl cellulose(TC5E, Shin-Etsu Chemical Co., Ltd.) were dissolved in a mixture of2,640 g methanol and 2,640 g dichloromethane. Three-hundred grams sodiumchloride (Shin Nihon Salt Co., Ltd., EF-70 classification, mean particlediameter of approximately 67 μm, particle diameter of 75 μm or smaller)were introduced to a fluidized bed granulator (Freund Industries,uni-glatt) and coated with this solution by the side spraying method(spraying liquid volume 16 g/min, spraying air pressure 3 kg/cm²,product temperature 30° C., inlet temperature 75° C.) to obtainacetaminophen particles.

Separately, 45.9 g ethyl cellulose (Nissin Chemistry Co.) and 5.1 ghydroxypropylmethyl cellulose (TC5E, brand name, Shin-Etsu Chemical Co.,Ltd.) were dissolved in a mixture of 48.5 g purified water and 920.5 gmethanol. Three-hundred forty grams acetaminophen particles wereintroduced to a fluidized bed granulator (Freund Industries, uni-glatt)and coated with this solution by side spraying (spraying liquid volumeof 8 g/min, spraying air pressure of 2.5 kg/cm², product temperature of39° C., inlet temperature of 75° C.) to obtain sustained-release fineparticles. Then 116.4 g of these sustained-release fine particles and542.7 g mannitol (Towa Kasei Co., Ltd) that had been pulverized by a pinmill pulverizing device (Hosokawa Micron) were granulated (sprayingliquid volume 15 g/min, spraying air pressure of 1.1 kg/cm², producttemperature of 28° C., inlet temperature of 35° C., spraying cycle of 20seconds spraying-40 seconds drying) with an aqueous 30% w/w solutioncontaining 117 g maltose (Hayashibara Co., Ltd., brand name: Sunmalt S)in a fluidized bed granulator (Freund Industries, uni-glatt) to obtainthe composition of the present invention. The ratio of ungranulatedsustained-release fine particles was 1.6%.

After further mixing 3.9 g magnesium stearate with the composition thatwas obtained, 520 mg tablets containing 50 mg acetaminophen per tabletwere made under a tableting pressure of 200 kg/punch and an initialhardness of 1.9 kp using a rotary tableting machine. Next, these tabletswere kept for 24 hours while heating and humidifying at 25° C./75% RHusing a thermostatic chamber at constant humidity (Tabaiespec Co., Ltd.,PR-35C). Then they were dried for 3 hours at 30° C. and 40% RH. Thetablets that were obtained showed a hardness of 6.4 kp (n=5), friabilityof 1.13% (100 rounds), and disintegration time in the buccal cavity of21 seconds (n=1). Moreover, as a result of evaluating uniformity ofcontent, CV %=3.3%, confirming that there is good uniformity of content.Furthermore, when dissolution of the sustained-release fine particlesand tablet was compared 2.5 hours after starting dissolution tests (timewhen there is approximately 30% dissolution of sustained-release fineparticles), 5 hours after (time when there is approximately 50%dissolution of sustained-release fine particles), and 9.5 hours after(time when there is approximately 80% dissolution of sustained-releasefine particles) and the difference was calculated, it was 8.8% at 2.5hours, 6.3% at 5 hours, and 3.3% at 9.5 hours, confirming thatacceleration of dissolution of sustained-release fine particles isprevented at any time.

EXAMPLE 6

Forty grams ethyl cellulose (Nissin Chemistry Co.) were dissolved in amixture of 380 g methanol and 380 g dichloromethane. Four-hundred gramssodium chloride (Shin Nihon Salt Co., Ltd., EF-70 classification, meanparticle diameter of approximately 67 μm, particle diameter of 75 μm orsmaller) were introduced to a fluidized bed granulator (FreundIndustries, uni-glatt) and coated with this solution by the sidespraying method (spraying liquid volume 6 g/min, spraying air pressure 2kg/cm², product temperature 28° C., inlet temperature 60° C.) to obtaincore particles. Then 1,200 g acetaminophen (Yoshitomi Fine ChemicalsCo., Ltd.) and 120 g hydroxypropylmethyl cellulose (TC5E, Shin-EtsuKagaku Co., Ltd.) were dissolved in a mixture of 2,640 g methanol and2,640 g dichloromethane. Three-hundred grams of the above-mentioned coreparticles were introduced to a fluidized bed granulator (FreundIndustries, uni-glatt) and coated with this solution by the sidespraying method (spraying liquid volume 15 g/min, spraying air pressure3 kg/cm², product temperature 30° C., inlet temperature 70° C.) toobtain acetaminophen particles.

Separately, 47.2 g ethyl cellulose (Nissin Chemistry Co.) and 5.3 ghydroxypropylmethyl cellulose (TC5E, brand name, Shin-Etsu Chemical Co.,Ltd.) were dissolved in a mixture of 49.9 g purified water and 947.6 gmethanol. Three-hundred fifty grams acetaminophen particles wereintroduced to a fluidized bed granulator (Freund Industries, uni-glatt)and coated with this solution by side spraying (spraying liquid volumeof 8 g/min, spraying air pressure of 2.5 kg/cm², product temperature of37° C., inlet temperature of 75° C.) to obtain sustained-release fineparticles. Then 116.4 g of these sustained-release fine particles and542.7 g mannitol (Towa Kasei Co., Ltd) that had been pulverized by a pinmill pulverizing device (Hosokawa Micron Co., Ltd.) were granulated(spraying liquid volume 15 g/min, spraying air pressure of 1.1 kg/cm²,product temperature of 30° C., inlet temperature of 40° C., sprayingcycle of 20 seconds spraying-40 seconds drying) with an aqueous 30% w/wsolution containing 117 g maltose (Hayashibara Co., Ltd., brand name:Sunmalt S) in a fluidized bed granulator (Freund Industries, uni-glatt)to obtain the composition of the present invention. The ratio ofungranulated sustained-release fine particles was 3.9%.

After further mixing 3.9 g magnesium stearate with the composition thatwas obtained, 520 mg tablets containing 50 mg acetaminophen per tabletwere made under a tableting pressure of 140 kg/punch and an initialhardness of 2.6 kp using a rotary tableting machine. Next, these tabletswere kept for 24 hours while heating and humidifying at 25° C./75% RHusing a thermostatic chamber at constant humidity (Tabaiespec Co., Ltd.,PR-35C). Then they were dried for 3 hours at 30° C. and 40% RH. Thetablets that were obtained showed a hardness of 5.9 kp (n=5), friabilityof 1.64% (100 rounds), and disintegration time in the buccal cavity of26 seconds (n=1). Moreover, as a result of evaluating uniformity ofcontent, CV %=2.0%, confirming that there is good uniformity of content.Furthermore, when dissolution of the sustained-release fine particlesand tablet was compared 2.3 hours after starting dissolution tests (timewhen there is approximately 30% dissolution of sustained-release fineparticles), 5.5 hours after (time when there is approximately 50%dissolution of sustained-release fine particles), and 13.5 hours after(time when there is approximately 80% dissolution of sustained-releasefine particles) and the difference was calculated, it was 0.6% at 2.3hours, 1.2% at 5.5 hours, and 3.2% at 13.5 hours, confirming thatacceleration of dissolution of sustained-release fine particles isprevented at any time.

EXAMPLE 7

Eighty grams tamsulosin hydrochloride and 80 g hydroxypropyl[methyl]cellulose (TC5E, Shin-Etsu Chemical Co., Ltd.) were dissolved in amixture of 304 g purified water and 2,736 g methanol. Four-thousandgrams Celphere 102 (brand name, Asahi Kasei, mean particle diameter ofapproximately 127 μm, particle diameter of approximately 50 toapproximately 150 μm) were introduced to a fluidized bed granulator(Freund Industries, FLO-5) and coated with this solution by the sidespraying method (spraying liquid volume 100 g/min, spraying air pressure4 kg/cm², product temperature 40° C., inlet temperature 80° C.) toobtain tamsulosin hydrochloride particles.

Separately, 43.7 g ethyl cellulose (Nissin Chemistry Co.) and 12.3 ghydroxypropylmethyl cellulose (TC5E, brand name, Shin-Etsu Chemical Co.,Ltd.) were dissolved in a mixture of 43.9 g purified water and 833.4 gmethanol. Four-hundred grams tamsulosin hydrochloride particles wereintroduced to a fluidized bed granulator (Freund Industries, uni-glatt)and coated with this solution by side spraying (spraying liquid volumeof 6 g/min, spraying air pressure of 4 kg/cm², product temperature of40° C., inlet temperature of 63° C.) to obtain sustained-release fineparticles.

Next, 300 g of these sustained-release fine particles were introduced toa fluidized bed granulator (Freund Industries, uni-glatt) and coatedwith a mixture of 90 g Aquacoat (brand name, Asahi Kasei), 180 gEudragit L30D55 (brand name, Röhm), 30 g Eudragit NE30D (brand name,Röhm), and 300 g purified water (spraying liquid volume of 6 g/min,spraying air pressure of 3 kg/cm², product temperature of 40° C., inlettemperature of 75.5° C.) to obtain enteric sustained-release fineparticles. Then 92.5 g of these enteric sustained-release fineparticles, 568.2 g mannitol (Towa Kasei Co., Ltd.) and 142.1 g lactose(Domomilk) that had been pulverized with a pin mill pulverizing device(Hosokawa Co., Ltd.), and 72 g erythritol (Nikken Chemicals Co., Ltd.)were granulated (spraying liquid volume 15 g/min, spraying air pressureof 0.5 kg/cm², product temperature of 40° C., inlet temperature of 70°C., spraying cycle of 15 seconds spraying-30 seconds drying) with anaqueous 5% w/w solution containing 18 g copolyvidone (BASF Co., brandname Kollidon VA64) in a fluidized bed granulator (Freund Industries,uni-glatt) to obtain the composition of the present invention. The ratioof ungranulated fine particles was 3.0%.

After further mixing 7.2 g calcium stearate with the composition thatwas obtained, 300 mg tablets containing 0.4 mg tamsulosin hydrochlorideper tablet were made under an initial hardness of 0.6 kp using a rotarytableting machine. Next, these tablets were heated for 13 minutes at120° C. using a program oven (model No. MOV-112P, Sanyo Corporation) andthen cooled at room temperature for 30 minutes. The tablets that wereobtained showed a hardness of 6.8 kp (n=5), friability of 0.28% (100rounds) and disintegration time in the buccal cavity of 27 seconds(n=1). Moreover, as a result of evaluating uniformity of content, CV%=1.6%, proving that there is good uniformity of content. Furthermore,when dissolution of the sustained-release fine particles and tablet wascompared 1 hour after starting dissolution tests (time when there isapproximately 30% dissolution of sustained-release fine particles), 2hours after (time when there is approximately 50% dissolution ofsustained-release fine particles), and 6 hours after (time when there isapproximately 80% dissolution of sustained-release fine particles) andthe difference was calculated, it was 1.1% at 1 hour, 2.8% at 5 [sic]hours, and 9.4% at 6 hours, confirming that acceleration of dissolutionof sustained-release fine particles is prevented at any time.

EXAMPLE 8

First, 1,200 g nicardipine hydrochloride and 1,200 g hydroxypropylmethylcellulose (TC5E, Shin-Etsu Chemical Co., Ltd.) were dissolved in amixture of 4,800 g methanol and 4,800 g dichloromethane. Three-hundredgrams silicon dioxide (Silica Gel, Sigma, mean particle diameter ofapproximately 48 μm, particle diameter of 75 μm or smaller) wereintroduced to a fluidized bed granulator (Freund Industries, uni-glatt)and coated with this solution by the side spraying method (sprayingliquid volume 18 g/min, spraying air pressure 3 kg/cm², producttemperature 30° C., inlet temperature 70° C.) to obtain nicardipinehydrochloride particles.

Separately, 54 g ethyl cellulose (Nissin Chemistry Co.) and 6 ghydroxypropylmethyl cellulose (TC5E, brand name, Shin-Etsu Chemical Co.,Ltd.) were dissolved in a mixture of 57 g purified water and 1,083 gmethanol. Three-hundred grams nicardipine hydrochloride particles wereintroduced to a fluidized bed granulator (Freund Industries, uni-glatt)and coated with this solution by side spraying (spraying liquid volumeof 8 g/min, spraying air pressure of 2.5 kg/cm², product temperature of39° C., inlet temperature of 70° C.) to obtain sustained-release fineparticles.

Sixty grams of these sustained-release fine particles, 254.4 g mannitol(Towa Kasei Co., Ltd.) and 63.6 g lactose (Domomilk) that had beenpulverized with a pin mill pulverizing device (Hosokawa Micron), and 12g erythritol (Nikken Chemicals Co., Ltd.) were granulated (sprayingliquid volume 15 g/min, spraying air pressure of 0.5 kg/cm², producttemperature of 39° C., inlet temperature of 50° C., spraying cycle of 5seconds spraying-15 seconds drying) with an aqueous 5% w/w solutioncontaining 8 g copolyvidone (BASF Co., brand name Kollidon VA64) in afluidized bed granulator (Freund Industries, uni-glatt) to obtain thecomposition of the present invention. The ratio of ungranulated fineparticles was 7.9%.

After further mixing 2 g magnesium stearate with the composition thatwas obtained, 400 mg tablets containing 20 mg nicardipine hydrochlorideper tablet were made under an initial hardness of 0.6 kp using a rotarytableting machine. Next, these tablets were heated for 10 minutes at130° C. using a program oven (model No. MOV-112P, Sanyo Corporation).Then they were cooled at room temperature for thirty minutes. Thetablets that were obtained showed a hardness of 3.7 kp (n=5), friabilityof 0.1% or less (100 rounds) and disintegration time in the buccalcavity of 20 seconds (n=1). Moreover, as a result of evaluatinguniformity of content, CV %=1.1%, proving that there is good uniformityof content. Furthermore, when dissolution of the sustained-release fineparticles and tablet was compared 0.5 hour after starting dissolutiontests (time when there is approximately 30% dissolution ofsustained-release fine particles), 2 hours after (time when there isapproximately 50% dissolution of sustained-release fine particles), and5.5 hours after (time when there is approximately 80% dissolution ofsustained-release fine particles) and the difference was calculated, itwas 10.3% at 0.5 hour, 12.8% at 2 hours, and 6.6% at 5.5 hours,confirming that acceleration of dissolution of sustained-release fineparticles is prevented at any time.

EXAMPLE 9

Eighty grams tamsulosin hydrochloride and 80 g hydroxypropylmethylcellulose (TC5E, Shin-Etsu Chemical Co., Ltd.) were dissolved in amixture of 304 g purified water and 2,736 g methanol. Four-thousandgrams Celphere 102 (brand name, Asahi Kasei, mean particle diameter ofapproximately 127 μm, particle diameter of approximately 50 toapproximately 150 μm) were introduced to a fluidized bed granulator(Freund Industries, FLO-5) and coated with this solution by the sidespraying method (spraying liquid volume 100 g/min, spraying air pressure4 kg/cm², product temperature 40° C., inlet temperature 80° C.) toobtain tamsulosin hydrochloride particles.

Separately, 561.6 g ethyl cellulose (Nissin Chemistry Co., Ltd.) and158.4 g hydroxypropylmethyl cellulose (TC5E, brand name, Shin-EtsuChemical Co., Ltd.) were dissolved in a mixture of 564 g purified waterand 10,716 g methanol. Four-thousand grams tamsulosin hydrochlorideparticles were introduced to a fluidized bed granulator (FreundIndustries, FLO-5) and coated with this solution by side spraying(spraying liquid volume of 40 g/min, spraying air pressure of 4 kg/cm²,product temperature of 40° C., inlet temperature of 54° C.) to obtainsustained-release fine particles.

Next, 4,000 g of these sustained-release fine particles were introducedto a fluidized bed granulator (Freund Industries, FLO-5) and coated witha mixture of 800 g Aquacoat (brand name, Asahi Kasei), 1,600 g EudragitL30D55 (brand name, Röhm), 266.7 g Eudragit NE30D (brand name, Röhm),and 5,333 g purified water (spraying liquid volume of 60 g/min, sprayingair pressure of 4.5 kg/cm², product temperature of 50° C., inlettemperature of 84° C.) to obtain enteric sustained-release fineparticles.

Then 392.7 g of these enteric sustained-release fine particles and2,540.2 [g] mannitol (Towa Kasei Co., Ltd.) and 635.1 g lactose(Domomilk) that had been pulverized with a pin mill pulverizing device(Hosokawa Co., Ltd.) were granulated (spraying liquid volume 100 g/min,spraying air pressure of 1.5 kg/cm², product temperature of 33° C.,inlet temperature of 48° C., spraying cycle of 20 seconds spraying-30seconds drying) with an aqueous 20% w/w solution containing 400 gmaltose (Hayashibara Co., Ltd., brand name: Sunmalt S) in a fluidizedbed granulator (Freund Industries, FLO-5) to obtain the composition ofthe present invention. The ratio of ungranulated fine particles was1.1%.

After further mixing 32 g calcium stearate with the composition that wasobtained, 300 mg tablets containing 0.4 mg tamsulosin hydrochloride pertablet were made under an initial hardness of 2.1 kp using a rotarytableting machine. Next, these tablets were kept for 24 hours whileheating and humidifying at 25° C./75% RH using a thermostatic chamber atconstant humidity (Tabaiespec Co., Ltd., PR-35C). Then they were driedfor 3 hours at 30° C. and 40% RH. The tablets that were obtained showeda hardness of 4.1 kp (n=5), friability of 1.67% (100 rounds) anddisintegration time in the buccal cavity of 20 seconds (n=1). Moreover,as a result of evaluating uniformity of content, CV %=1.6%, proving thatthere is good uniformity of content. Furthermore, when dissolution ofthe sustained-release fine particles and tablet was compared 2 hoursafter starting dissolution tests (time when there is approximately 30%dissolution of sustained-release fine particles), 4 hours after (timewhen there is approximately 50% dissolution of sustained-release fineparticles), and 8 hours after (time when there is approximately 80%dissolution of sustained-release fine particles) and the difference wascalculated, it was 7.5% at 2 hours, 6.4% at 4 hours, and 1.5% at 8hours, confirming that acceleration of dissolution of sustained-releasefine particles is prevented at any time.

INDUSTRIAL APPLICABILITY

The present invention relates to a composition comprisingsustained-release fine particles for providing what at a glance arecontradictory functions in that the tablets have sustained releasabilityeven though they quickly disintegrate and dissolve in the buccal cavity.Moreover, the present invention is characterized in that it makes itpossible to inhibit acceleration of the drug dissolution after makingtablets that is the result of destruction of the sustained-release fineparticles under tableting pressure when tablets are made, and to realizecontrolled dissolution, which is the design goal of sustained-releasefine particle preparation, with good reproducibility, even after tabletshave been made. Therefore, pharmaceutical preparation design of thesustained-release fine particles is simplified, and there is further thecharacteristic of making it possible to guarantee good uniformity ofdrug content. Furthermore, it is possible to present a compositioncomprising sustained-release fine particles that will have a profoundeffect in the development of an assortment of quick-disintegratingtablets in the buccal cavity during the step of making thequick-disintegrating tablets in the buccal cavity comprisingsustained-release fine particles into a product, particularly during thestep of industrial manufacture, and further, the step of qualityassurance.

1. A composition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity, characterized in thatit comprises the product granulation of sustained-release fine particlescontaining a drug and one or two or more fillers selected from the groupconsisting of sugars or sugar alcohols with a binder forquick-disintegrating tablets in the buccal cavity, and in that the ratioof ungranulated sustained-release fine particles in the entirecomposition is 0 to 15%.
 2. The composition comprising sustained-releasefine particles for quick-disintegrating tablets in the buccal cavity ofclaim 1, wherein the binder for quick-disintegrating tablets in thebuccal cavity is one or two or more selected from the group consistingof saccharides of high moldability, water-soluble polymer substances,and saccharides with a low melting point.
 3. The composition comprisingsustained-release fine particles for quick-disintegrating tablets in thebuccal cavity of claim 2, wherein the sugar or sugar alcohol is one ortwo or more selected from the group consisting of saccharides with lowmoldability, saccharides with a high melting point, and saccharides witha low melting point.
 4. The composition comprising sustained-releasefine particles for quick-disintegrating tablets in the buccal cavity ofclaim 3, wherein the mixture ratio of sustained-release fine particles,filler, and binder for quick-disintegrating tablets in the buccal cavityis 1 to 50%, 20 to 98%, and 1 to 30%, respectively.
 5. The compositioncomprising sustained-release fine particles for quick-disintegratingtablets in the buccal cavity of claim 4, wherein the mean particlediameter of the sustained-release fine particles is approximately 0.1 μmto approximately 350 μm.
 6. The composition comprising sustained-releasefine particles for quick-disintegrating tablets in the buccal cavity ofclaim 5, wherein the sustained-release fine particles consist of atleast crystal cellulose particles, drug, and polymer substance.
 7. Thecomposition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity of claim 6, whereinthe drug is tamsulosin hydrochloride.
 8. The composition comprisingsustained-release fine particles for quick-disintegrating tablets in thebuccal cavity of claim 7, wherein the sustained-release fine particlesare enteric sustained-release fine particles.
 9. The compositioncomprising sustained-release fine particles for quick-disintegratingtablets in the buccal cavity of claim 8, wherein the polymer substancesis hydroxypropylmethyl cellulose, ethyl cellulose, methacrylicacid-ethyl acrylate copolymer and ethyl acrylate-methyl methacrylatecopolymer dispersion.
 10. The composition comprising sustained-releasefine particles for quick-disintegrating tablets in the buccal cavity ofclaim 9, wherein the binder for quick-disintegrating tablets in thebuccal cavity is one or two or more selected from the group consistingof maltose, trehalose, sorbitol, and maltitol.
 11. Quick-disintegratingtablets in the buccal cavity consisting of the composition comprisingsustained-release fine particles of claim
 10. 12. Thequick-disintegrating tablets in the buccal cavity of claim 11,characterized in that the coefficient of variation (CV %) of the amountof drug, which is an indicator of uniformity of content, is 3.5% orless.
 13. A method of manufacturing a composition comprisingsustained-release fine particles for quick-disintegrating tablets in thebuccal cavity, characterized in that it comprises the product ofgranulation of sustained-release fine particles containing a drug andone or two or more fillers selected from the group consisting of sugarsor sugar alcohols with a binder for quick-disintegrating tablets in thebuccal cavity, and in that the ratio of ungranulated sustained-releasefine particles in the entire composition is 0 to 15%.
 14. The method ofmanufacturing a composition comprising sustained-release fine particlesfor quick-disintegrating tablets in the buccal cavity of claim 13,wherein the binder for quick-disintegrating tablets in the buccal cavityis one or two or more selected from the group consisting of saccharidesof high moldability, water-soluble polymer substances, and saccharideswith a low melting point.
 15. The method of manufacturing a compositioncomprising sustained-release fine particles for quick-disintegratingtablets in the buccal cavity of claim 14, wherein the sugar or sugaralcohol is one or two or more selected from the group consisting ofsaccharides with low moldability, saccharides with a high melting point,and saccharides with a low melting point.
 16. The method ofmanufacturing a composition comprising sustained-release fine particlesfor quick-disintegrating tablets in the buccal cavity of claim 15,wherein the mixture ratio of sustained-release fine particles, filler,and binder for quick-disintegrating tablets in the buccal cavity is 1 to50%, 20 to 98%, and 1 to 30%, respectively.
 17. The method ofmanufacturing a composition comprising sustained-release fine particlesfor quick-disintegrating tablets in the buccal cavity of claim 16,wherein the mean particle diameter of the sustained-release fineparticles is approximately 0.1 μm to approximately 350 μm.
 18. Themethod of manufacturing a composition comprising sustained-release fineparticles for quick-disintegrating tablets in the buccal cavity of claim17, wherein the sustained-release fine particles consist of at leastcrystal cellulose particles, drug, and polymer substance.
 19. The methodof manufacturing a composition comprising sustained-release fineparticles for quick-disintegrating tablets in the buccal cavity of claim18, wherein the drug is tamsulosin hydrochloride.
 20. The method ofmanufacturing composition comprising sustained-release fine particlesfor quick-disintegrating tablets in the buccal cavity of claim 19,wherein the sustained-release fine particles are entericsustained-release fine particles.
 21. The method of manufacturing acomposition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity of claim 20, whereinthe polymer substance is hydroxypropylmethyl cellulose, ethyl cellulose,methacrylic acid-ethyl acrylate copolymer and ethyl acrylate-methylmethacrylate copolymer dispersion.
 22. The method of manufacturing acomposition comprising sustained-release fine particles forquick-disintegrating tablets in the buccal cavity of claim 21, whereinthe binder for quick-disintegrating tablets in the buccal cavity is oneor two or more selected from the group consisting of maltose, trehalose,sorbitol, and maltitol.
 23. A method of manufacturingquick-disintegrating tablets in the buccal cavity consisting of thecomposition comprising sustained-release fine particles of claim
 22. 24.The method of manufacturing quick-disintegrating tablets in the buccalcavity of claim 23, characterized in that the coefficient of variation(CV %) of the amount of drug, which is an indicator of uniformity ofcontent, is 3.5% or less.